917 results on '"Barjaktarevic, Igor"'
Search Results
2. Eosinophil recovery in hospitalized COVID-19 patients is associated with lower rates of ICU admission and in-hospital mortality: An observational cohort analysis
- Author
-
Yan, Peter D, Markovic, Daniela, Hixson, Roxana Y, Shover, Carolyn M, Buhr, Russell G, Salehi-Rad, Ramin, LeMaster, Blake, Tashkin, Donald P, Fulcher, Jennifer A, and Barjaktarevic, Igor Z
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Health Sciences ,Good Health and Well Being ,Humans ,Eosinophils ,COVID-19 ,Hospital Mortality ,Hospitalization ,Cohort Studies ,Intensive Care Units ,ARDS ,Critical illness ,Eosinophil ,In flammation ,Survival ,Inflammation ,Respiratory System - Abstract
BackgroundAdmission eosinopenia (
- Published
- 2023
3. Integration and evaluation of chest X-ray artificial intelligence in clinical practice.
- Author
-
Wong, Koon-Pong, Homer, Suzanne, Wei, Sindy, Yaghmai, Nazanin, Estrada Paz, Oscar, Young, Timothy, Buhr, Russell, Barjaktarevic, Igor, Shrestha, Liza, Daly, Morgan, Goldin, Jonathan, Enzmann, Dieter, and Brown, Matthew
- Subjects
artificial intelligence ,chest x-ray ,clinical translation ,endotracheal tube ,user survey - Abstract
PURPOSE: To integrate and evaluate an artificial intelligence (AI) system that assists in checking endotracheal tube (ETT) placement on chest x-rays (CXRs) in clinical practice. APPROACH: In clinical use over 17 months, 214 CXR images were ordered to check ETT placement with AI assistance by intensive care unit (ICU) physicians. The system was built on the SimpleMind Cognitive AI platform and integrated into a clinical workflow. It automatically identified the ETT and checked its placement relative to the trachea and carina. The ETT overlay and misplacement alert messages generated by the AI system were compared with radiology reports as the reference. A survey study was also conducted to evaluate usefulness of the AI system in clinical practice. RESULTS: The alert messages indicating that either the ETT was misplaced or not detected had a positive predictive value of 42% (21/50) and negative predictive value of 98% (161/164) based on the radiology reports. In the survey, radiologist and ICU physician users indicated that they agreed with the AI outputs and that they were useful. CONCLUSIONS: The AI system performance in real-world clinical use was comparable to that seen in previous experiments. Based on this and physician survey results, the system can be deployed more widely at our institution, using insights gained from this evaluation to make further algorithm improvements and quality assurance of the AI system.
- Published
- 2023
4. Blood Gene Expression and Immune Cell Subtypes Associated with Chronic Obstructive Pulmonary Disease Exacerbations.
- Author
-
Ryu, Min, Yun, Jeong, Morrow, Jarrett, Saferali, Aabida, Castaldi, Peter, Chase, Robert, Stav, Meryl, Xu, Zhonghui, Barjaktarevic, Igor, Han, MeiLan, Labaki, Wassim, Huang, Yvonne, Christenson, Stephanie, ONeal, Wanda, Bowler, Russell, Sin, Don, Freeman, Christine, Curtis, Jeffrey, and Hersh, Craig
- Subjects
COPD exacerbation ,RNA sequencing ,chronic obstructive pulmonary disease ,circulating leukocytes ,immune phenotyping ,Humans ,CD8-Positive T-Lymphocytes ,Prospective Studies ,Disease Progression ,Pulmonary Disease ,Chronic Obstructive ,Transcriptome - Abstract
Rationale: Acute exacerbations of chronic obstructive pulmonary disease (AE-COPDs) are associated with a significant disease burden. Blood immune phenotyping may improve our understanding of a COPD endotype at increased risk of exacerbations. Objective: To determine the relationship between the transcriptome of circulating leukocytes and COPD exacerbations. Methods: Blood RNA sequencing data (n = 3,618) from the COPDGene (Genetic Epidemiology of COPD) study were analyzed. Blood microarray data (n = 646) from the ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints) study were used for validation. We tested the association between blood gene expression and AE-COPDs. We imputed the abundance of leukocyte subtypes and tested their association with prospective AE-COPDs. Flow cytometry was performed on blood in SPIROMICS (Subpopulations and Intermediate Outcomes in COPD Study) (n = 127), and activation markers for T cells were tested for association with prospective AE-COPDs. Measurements and Main Results: Exacerbations were reported 4,030 and 2,368 times during follow-up in COPDGene (5.3 ± 1.7 yr) and ECLIPSE (3 yr), respectively. We identified 890, 675, and 3,217 genes associated with a history of AE-COPDs, persistent exacerbations (at least one exacerbation per year), and prospective exacerbation rate, respectively. In COPDGene, the number of prospective exacerbations in patients with COPD (Global Initiative for Chronic Obstructive Lung Disease stage ⩾2) was negatively associated with circulating CD8+ T cells, CD4+ T cells, and resting natural killer cells. The negative association with naive CD4+ T cells was replicated in ECLIPSE. In the flow-cytometry study, an increase in CTLA4 on CD4+ T cells was positively associated with AE-COPDs. Conclusions: Individuals with COPD with lower circulating lymphocyte counts, particularly decreased CD4+ T cells, are more susceptible to AE-COPDs, including persistent exacerbations.
- Published
- 2023
5. African American race is associated with worse sleep quality in heavy smokers.
- Author
-
Baugh, Aaron, Acho, Megan, Arhin, Abraham, Barjaktarevic, Igor, Couper, David, Criner, Gerard, Han, Meilan, Hansel, Nadia, Krishnan, Jerry, Malcolm, Katherine, Namen, Andrew, Peters, Stephen, Schotland, Helena, Sowho, Mudiaga, Zeidler, Michelle, Woodruff, Prescott, and Thakur, Neeta
- Subjects
COPD ,PSQI ,SES ,health disparities ,sleep ,socioeconomic status ,validation ,Humans ,Female ,Smokers ,Black or African American ,Sleep Quality ,Quality of Life ,Pulmonary Disease ,Chronic Obstructive - Abstract
STUDY OBJECTIVES: To examine the association of self-identified race with sleep quality in heavy smokers. METHODS: We studied baseline data from 1965 non-Hispanic White and 462 African American participants from SPIROMICS with ≥ 20 pack-years smoking history. We first examined the Pittsburgh Sleep Quality Indexs (PSQI) internal consistency and item-total correlation in a population with chronic obstructive pulmonary disease. We then used staged multivariable regression to investigate the association of race and sleep quality as measured by the PSQI) The first model included demographics, the second added measures of health status, and the third, indicators of socioeconomic status. We next explored the correlation between sleep quality with 6-minute walk distance and St. Georges Respiratory Questionnaire score as chronic obstructive pulmonary disease-relevant outcomes. We tested for interactions between self-identified race and the most important determinants of sleep quality in our conceptual model. RESULTS: We found that the PSQI had good internal consistency and item-total correlation in our study population of heavy smokers with and without chronic obstructive pulmonary disease. African American race was associated with increased PSQI in univariable analysis and after adjustment for demographics, health status, and socioenvironmental exposures (P = .02; 0.44 95%CI: .06 to .83). Increased PSQI was associated with higher postbronchodilator forced expiratory volume in 1 second and lower household income, higher depressive symptoms, and female sex. We identified an interaction wherein depressive symptoms had a greater impact on PSQI score for non-Hispanic White than African American participants (P for interaction = .01). CONCLUSIONS: In heavy smokers, self-reported African American race is independently associated with worse sleep quality. CLINICAL TRIAL REGISTRATION: Registry: ClinicalTrials.gov; Name: Study of COPD Subgroups and Biomarkers (SPIROMICS); URL: https://clinicaltrials.gov/ct2/show/NCT01969344; Identifier: NCT01969344. CITATION: Baugh AD, Acho M, Arhin A, et al. African American race is associated with worse sleep quality in heavy smokers. J Clin Sleep Med. 2023;19(8):1523-1532.
- Published
- 2023
6. Changes in Lung Volumes with Spirometric Disease Progression in COPD.
- Author
-
Barr, R, Bleecker, Eugene, Buhr, Russell, Criner, Gerard, Comellas, Alejandro, Couper, David, Curtis, Jeffrey, Dransfield, Mark, Fortis, Spyridon, Han, MeiLan, Hansel, Nadia, Hoffman, Eric, Hokanson, John, Kaner, Robert, Kanner, Richard, Krishnan, Jerry, Labaki, Wassim, Lynch, David, Ortega, Victor, Peters, Stephen, Woodruff, Prescott, Cooper, Christopher, Bowler, Russell, Paine, Robert, Rennard, Stephen, Tashkin, Donald, Arjomandi, Mehrdad, Zeng, Siyang, Chen, Jianhong, Bhatt, Surya, Abtin, Fereidoun, and Barjaktarevic, Igor
- Subjects
COPD ,air trapping ,computed tomography ,early disease ,lung volumes - Abstract
BACKGROUND: Abnormal lung volumes representing air trapping identify the subset of smokers with preserved spirometry who develop spirometric chronic obstructive pulmonary disease (COPD) and adverse outcomes. However, how lung volumes evolve in early COPD as airflow obstruction develops remains unclear. METHODS: To establish how lung volumes change with the development of spirometric COPD, we examined lung volumes from the pulmonary function data (seated posture) available in the U.S. Department of Veterans Affairs electronic health records (n=71,356) and lung volumes measured by computed tomography (supine posture) available from the COPD Genetic Epidemiology (COPDGene®) study (n=7969) and the SubPopulations and InterMediate Outcome Measures In COPD Study (SPIROMICS) (n=2552) cohorts, and studied their cross-sectional distributions and longitudinal changes across the airflow obstruction spectrum. Patients with preserved ratio-impaired spirometry (PRISm) were excluded from this analysis. RESULTS: Lung volumes from all 3 cohorts showed similar patterns of distributions and longitudinal changes with worsening airflow obstruction. The distributions for total lung capacity (TLC), vital capacity (VC), and inspiratory capacity (IC) and their patterns of change were nonlinear and included different phases. When stratified by airflow obstruction using Global initiative for chronic Obstructive Lung Disease (GOLD) stages, patients with GOLD 1 (mild) COPD had larger lung volumes (TLC, VC, IC) compared to patients with GOLD 0 (smokers with preserved spirometry) or GOLD 2 (moderate) disease. In longitudinal follow-up of baseline GOLD 0 patients who progressed to spirometric COPD, those with an initially higher TLC and VC developed mild obstruction (GOLD 1) while those with an initially lower TLC and VC developed moderate obstruction (GOLD 2). CONCLUSIONS: In COPD, TLC, and VC have biphasic distributions, change in nonlinear fashions as obstruction worsens, and could differentiate those GOLD 0 patients at risk for more rapid spirometric disease progression.
- Published
- 2023
7. Impact of Bronchiectasis on COPD Severity and Alpha-1 Antitrypsin Deficiency as a Risk Factor in Individuals with a Heavy Smoking History.
- Author
-
Izquierdo, Manuel, Marion, Chad, Genese, Frank, Newell, John, ONeal, Wanda, Li, Xingnan, Hawkins, Gregory, Barjaktarevic, Igor, Barr, R, Christenson, Stephanie, Cooper, Christopher, Couper, David, Curtis, Jeffrey, Han, Meilan, Hansel, Nadia, Kanner, Richard, Martinez, Fernando, Paine, Robert, Tejwani, Vickram, Woodruff, Prescott, Zein, Joe, Hoffman, Eric, Peters, Stephen, Meyers, Deborah, Bleecker, Eugene, and Ortega, Victor
- Subjects
COPD ,alpha-1 antitrypsin ,bronchiectasis ,lung function - Abstract
RATIONALE: Bronchiectasis is common among those with heavy smoking histories, but risk factors for bronchiectasis, including alpha-1 antitrypsin deficiency, and its implications for COPD severity are uncharacterized in such individuals. OBJECTIVES: To characterize the impact of bronchiectasis on COPD and explore alpha-1antitrypsin as a risk factor for bronchiectasis. METHODS: SubPopulations and InteRmediate Outcome Measures In COPD Study (SPIROMICS) participants (N=914; ages 40-80 years; ≥20-pack-year smoking) had high-resolution computed tomography (CT) scans interpreted visually for bronchiectasis, based on airway dilation without fibrosis or cicatrization. We performed regression-based models of bronchiectasis with clinical outcomes and quantitative CT measures. We deeply sequenced the gene encoding -alpha-1 antitrypsin, SERPINA1, in 835 participants to test for rare variants, focusing on the PiZ genotype (Glu366Lys, rs28929474). MEASUREMENTS AND MAIN RESULTS: We identified bronchiectasis in 365 (40%) participants, more frequently in women (45% versus 36%, p=0.0045), older participants (mean age=66[standard deviation (SD)=8.3] versus 64[SD=9.1] years, p=0.0083), and those with lower lung function (forced expiratory volume in 1 second [FEV1 ] percentage predicted=66%[SD=27] versus 77%[SD=25], p
- Published
- 2023
8. Impact of Marijuana Smoking on COPD Progression in a Cohort of Middle-Aged and Older Persons.
- Author
-
Cooper, Christopher, Shing, Tracie, Buhr, Russell, Hoffman, Eric, Woodruff, Prescott, Drummond, M, Kanner, Richard, Han, MeiLan, Hansel, Nadia, Bowler, Russell, Kinney, Gregory, Jacobson, Sean, Morris, Madeline, Martinez, Fernando, Ohar, Jill, Couper, David, Tashkin, Donald, and Barjaktarevic, Igor
- Subjects
COPD ,Exacerbations ,HRCT ,Marijuana ,Spirometry - Abstract
BACKGROUND: Limited data are available regarding marijuana smokings impact on the development or progression of chronic obstructive pulmonary disease (COPD) in middle-aged or older adults with a variable history of tobacco cigarette smoking. METHODS: We divided ever-tobacco smoking participants in the SubPopulations and InteRmediate Outcomes In COPD Study (SPIROMICS) into 3 groups based on self-reported marijuana use: current, former, or never marijuana smokers (CMSs, FMSs or NMSs, respectively). Longitudinal data were analyzed in participants with ≥2 visits over a period of ≥52 weeks. MEASUREMENTS: We compared CMSs, FMSs, and NMSs, and those with varying amounts of lifetime marijuana use. Mixed effects linear regression models were used to analyze changes in spirometry, symptoms, health status, and radiographic metrics; zero-inflated negative binomial models were used for exacerbation rates. All models were adjusted for age, sex, race, baseline tobacco smoking amount, and forced expiratory volume in 1 second (FEV1) %predicted. RESULTS: Most participants were followed for ≥4 years. Annual rates of change in FEV1, incident COPD, respiratory symptoms, health status, radiographic extent of emphysema or air trapping, and total or severe exacerbations were not different between CMSs or FMSs versus NMSs or between those with any lifetime amount of marijuana use versus NMSs. CONCLUSIONS: Among SPIROMICS participants with or without COPD, neither former nor current marijuana smoking of any lifetime amount was associated with evidence of COPD progression or its development. Because of our studys limitations, these findings underscore the need for further studies to better understand longer-term effects of marijuana smoking in COPD.
- Published
- 2023
9. Bronchodilator Responsiveness in Tobacco-Exposed People With or Without COPD
- Author
-
Fortis, Spyridon, Quibrera, Pedro M, Comellas, Alejandro P, Bhatt, Surya P, Tashkin, Donald P, Hoffman, Eric A, Criner, Gerard J, Han, MeiLan K, Barr, R Graham, Arjomandi, Mehrdad, Dransfield, Mark B, Peters, Stephen P, Dolezal, Brett A, Kim, Victor, Putcha, Nirupama, Rennard, Stephen I, Paine, Robert, Kanner, Richard E, Curtis, Jeffrey L, Bowler, Russell P, Martinez, Fernando J, Hansel, Nadia N, Krishnan, Jerry A, Woodruff, Prescott G, Barjaktarevic, Igor Z, Couper, David, Anderson, Wayne H, Cooper, Christopher B, Investigators, Subpopulations and Intermediate Outcome Measures in COPD Study, Alexis, Neil E, Barjaktarevic, Igor, Basta, Patricia, Bateman, Lori A, Bleecker, Eugene R, Boucher, Richard C, Christenson, Stephanie A, Couper, David J, Crystal, Ronald G, Doerschuk, Claire M, Dransfield, Mark T, Drummond, Brad, Freeman, Christine M, Galban, Craig, Hastie, Annette T, Huang, Yvonne, Kaner, Robert J, Kleerup, Eric C, LaVange, Lisa M, Lazarus, Stephen C, Meyers, Deborah A, Moore, Wendy C, Newell, John D, Paulin, Laura, Pirozzi, Cheryl, Oelsner, Elizabeth C, O’Neal, Wanda K, Ortega, Victor E, Raman, Sanjeev, Wells, J Michael, and Wise, Robert A
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Clinical Sciences ,Clinical Research ,Lung ,Chronic Obstructive Pulmonary Disease ,Respiratory ,Good Health and Well Being ,Humans ,Bronchodilator Agents ,Nicotiana ,Retrospective Studies ,Forced Expiratory Volume ,Pulmonary Disease ,Chronic Obstructive ,Asthma ,Vital Capacity ,bronchodilator ,bronchodilator response ,bronchodilator responsiveness ,bronchodilator reversibility ,COPD ,Subpopulations and Intermediate Outcome Measures in COPD Study Investigators ,Respiratory System ,Cardiovascular medicine and haematology ,Clinical sciences - Abstract
BackgroundBronchodilator responsiveness (BDR) in obstructive lung disease varies over time and may be associated with distinct clinical features.Research questionIs consistent BDR over time (always present) differentially associated with obstructive lung disease features relative to inconsistent (sometimes present) or never (never present) BDR in tobacco-exposed people with or without COPD?Study design and methodsWe retrospectively analyzed data from 2,269 tobacco-exposed participants in the Subpopulations and Intermediate Outcome Measures in COPD Study with or without COPD. We used various BDR definitions: change of ≥ 200 mL and ≥ 12% in FEV1 (FEV1-BDR), change in FVC (FVC-BDR), and change in in FEV1, FVC or both (ATS-BDR). Using generalized linear models adjusted for demographics, smoking history, FEV1 % predicted after bronchodilator administration, and number of visits that the participant completed, we assessed the association of BDR group: (1) consistent BDR, (2) inconsistent BDR, and (3) never BDR with asthma, CT scan features, blood eosinophil levels, and FEV1 decline in participants without COPD (Global Initiative for Chronic Obstructive Lung Disease [GOLD] stage 0) and the entire cohort (participants with or without COPD).ResultsBoth consistent and inconsistent ATS-BDR were associated with asthma history and greater small airways disease (%parametric response mapping functional small airways disease) relative to never ATS-BDR in participants with GOLD stage 0 disease and the entire cohort. We observed similar findings using FEV1-BDR and FVC-BDR definitions. Eosinophils did not vary consistently among BDR groups. Consistent BDR was associated with FEV1 decline over time relative to never BDR in the entire cohort. In participants with GOLD stage 0 disease, both the inconsistent ATS-BDR group (OR, 3.20; 95% CI, 2.21-4.66; P < .001) and consistent ATS-BDR group (OR, 9.48; 95% CI, 3.77-29.12; P < .001) were associated with progression to COPD relative to the never ATS-BDR group.InterpretationDemonstration of BDR, even once, describes an obstructive lung disease phenotype with a history of asthma and greater small airways disease. Consistent demonstration of BDR indicated a high risk of lung function decline over time in the entire cohort and was associated with higher risk of progression to COPD in patients with GOLD stage 0 disease.
- Published
- 2023
10. OS-120 Fazirsiran reduces liver Z-alpha-1 antitrypsin synthesis, decreases globule burden and improves histological measures of liver disease in adults with alpha-1 antitrypsin deficiency: a randomized placebo-controlled phase 2 study
- Author
-
Clark, Virginia, Strange, Charlton, Strnad, Pavel, Sanchez, Antonio, Kwo, Paul Yien, Pereira, Vítor Magno, Van Hoek, Bart, Barjaktarevic, Igor, Corsico, Angelo Guido, Pons, Monica, Goldklang, Monica, Gray, Meagan, Kuhn, Brooks, Vargas, Hugo, Vierling, John M, Vuppalanchi, Raj, Brantly, Mark, Kappe, Naomi, Chang, Ting, Schluep, Thomas, Yi, Min, Hamilton, James, San Martin, Javier, and Loomba, Rohit
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oral and gastrointestinal ,Public Health and Health Services ,Gastroenterology & Hepatology ,Clinical sciences - Published
- 2023
11. Reduced quantity and function of pneumococcal antibodies are associated with exacerbations of COPD in SPIROMICS.
- Author
-
LaFon, David, Woo, Han, Fedarko, Neal, Azar, Antoine, Hill, Harry, Tebo, Anne, Martins, Thomas, Han, MeiLan, Krishnan, Jerry, Ortega, Victor, Kaner, Robert, Hastie, Annette, ONeal, Wanda, Couper, David, Woodruff, Prescott, Curtis, Jeffrey, Hansel, Nadia, Nahm, Moon, Dransfield, Mark, Putcha, Nirupama, and Barjaktarevic, Igor
- Subjects
Antibodies ,Immunity ,Immunoglobulin G ,Opsonization ,Streptococcus pneumoniae ,Humans ,Immunoglobulin G ,Streptococcus pneumoniae ,Vaccination ,Immunologic Tests ,Antibodies ,Bacterial ,Pulmonary Disease ,Chronic Obstructive ,Pneumococcal Vaccines ,Pneumococcal Infections - Abstract
While hypogammaglobulinemia is associated with COPD exacerbations, it is unknown whether frequent exacerbators have specific defects in antibody production/function. We hypothesized that reduced quantity/function of serum pneumococcal antibodies correlate with exacerbation risk in the SPIROMICS cohort. We measured total pneumococcal IgG in n = 764 previously vaccinated participants with COPD. In a propensity-matched subset of n = 200 with vaccination within five years (n = 50 without exacerbations in the previous year; n = 75 with one, n = 75 with ≥2), we measured pneumococcal IgG for 23 individual serotypes, and pneumococcal antibody function for 4 serotypes. Higher total pneumococcal IgG, serotype-specific IgG (17/23 serotypes), and antibody function (3/4 serotypes) were independently associated with fewer prior exacerbations. Higher pneumococcal IgG (5/23 serotypes) predicted lower exacerbation risk in the following year. Pneumococcal antibodies are inversely associated with exacerbations, supporting the presence of immune defects in frequent exacerbators. With further study, pneumococcal antibodies may be useful biomarkers for immune dysfunction in COPD.
- Published
- 2023
12. Clinical Implications of Low Absolute Blood Eosinophil Count in the SPIROMICS COPD Cohort.
- Author
-
LeMaster, W, Quibrera, P, Couper, David, Tashkin, Donald, Bleecker, Eugene, Doerschuk, Claire, Ortega, Victor, Cooper, Christopher, Han, MeiLan, Woodruff, Prescott, ONeal, Wanda, Anderson, Wayne, Alexis, Neil, Bowler, Russell, Barr, R, Kaner, Robert, Dransfield, Mark, Paine, Robert, Kim, Victor, Curtis, Jeffrey, Martinez, Fernando, Hastie, Annette, and Barjaktarevic, Igor
- Subjects
COPD ,GOLD group D ,eosinophil ,inhaled corticosteroid ,Female ,Humans ,Eosinophils ,Prospective Studies ,Pulmonary Disease ,Chronic Obstructive ,Adrenal Cortex Hormones ,Pulmonary Emphysema ,Emphysema ,Disease Progression ,Administration ,Inhalation - Abstract
BACKGROUND: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) considers blood eosinophil counts < 100 cells/μL (BEC≤100) in people with COPD to predict poor inhaled corticosteroid (ICS) responsiveness. However, the BEC≤100 phenotype is inadequately characterized, especially in advanced COPD. RESEARCH QUESTION: Are there differences between GOLD group D patients with high BEC and those with low BEC regarding baseline characteristics and longitudinal outcomes? STUDY DESIGN AND METHODS: We used multivariable mixed models and logistic regression to contrast clinical characteristics and outcomes of BEC≤100 vs BEC > 100 (BEC100+) in all subjects with COPD (n = 1,414) and GOLD group D subjects (n = 185) not receiving ICS. RESULTS: We identified n = 485 with BEC≤100 (n = 61 GOLD group D) and n = 929 people with BEC100+ (n = 124 GOLD group D). BEC≤100 status was stable at 6 weeks and approximately 52 weeks (intraclass correlations of 0.78 and 0.71, respectively). Compared with BEC100+, BEC≤100 comprised more women, with greater current smoking, and less frequent childhood asthma. Among all analyzed participants, the two BEC-defined subsets showed similar rates of lung function decline (mean slope, BEC≤100 vs BEC100+, -50 vs -39 mL/y; P = .140), exacerbations (0.40 vs 0.36/y; P = .098), subsequent ICS initiation (2.5% vs 4.4%; P = .071), and mortality (7.8% vs 8.4%; P = .715). However, in GOLD group D, people with BEC≤100 showed higher exacerbation rates within 365 days of enrollment (0.62 vs 0.33/y; P = .002) and total follow-up (1.16 vs 0.83/y; P = .014). They also had greater lung function decline (mean slope of -68 mL/y vs -23 mL/y; P = .036) and had greater emphysema at baseline (voxels < 950 Hounsfield units at total lung capacity of 7.46% vs 4.61%; P = .029). INTERPRETATION: In non-ICS-treated GOLD group D COPD, people with BEC≤100 had more baseline emphysema, prospective exacerbations, and lung function decline. Our analysis has identified a particularly vulnerable subpopulation of people with COPD, suggesting the need for studies focused specifically on their therapeutic treatment. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov; No.: NCT01969344; URL: www. CLINICALTRIALS: gov.
- Published
- 2023
13. Implications of Pleural Fluid Composition in Persistent Pleural Effusion following Orthotopic Liver Transplant.
- Author
-
Patel, Bhavesh H, Melamed, Kathryn H, Wilhalme, Holly, Day, Gwenyth L, Wang, Tisha, DiNorcia, Joseph, Farmer, Douglas, Agopian, Vatche, Kaldas, Fady, and Barjaktarevic, Igor
- Subjects
Pleura ,Exudates and Transudates ,Humans ,Pleural Effusion ,Liver Transplantation ,Retrospective Studies ,Light’s criteria ,exudative pleural effusion ,hepatic hydrothorax ,orthotopic liver transplantation ,Transplantation ,Patient Safety ,Good Health and Well Being - Abstract
Persistent pleural effusions (PPEf) represent a known complication of orthotopic liver transplant (OLT). However, their clinical relevance is not well described. We evaluated the clinical, biochemical, and cellular characteristics of post-OLT PPEf and assessed their relationship with longitudinal outcomes. We performed a retrospective cohort study of OLT recipients between 2006 and 2015. Included patients had post-OLT PPEf, defined by effusion persisting >30 days after OLT and available pleural fluid analysis. PPEf were classified as transudates or exudates (ExudLight) by Light's criteria. Exudates were subclassified as those with elevated lactate dehydrogenase (ExudLDH) or elevated protein (ExudProt). Cellular composition was classified as neutrophil- or lymphocyte-predominant. Of 1602 OLT patients, 124 (7.7%) had PPEf, of which 90.2% were ExudLight. Compared to all OLT recipients, PPEf patients had lower two-year survival (HR 1.63; p = 0.002). Among PPEf patients, one-year mortality was associated with pleural fluid RBC count (p = 0.03). While ExudLight and ExudProt showed no association with outcomes, ExudLDH were associated with increased ventilator dependence (p = 0.03) and postoperative length of stay (p = 0.03). Neutrophil-predominant effusions were associated with increased postoperative ventilator dependence (p = 0.03), vasopressor dependence (p = 0.02), and surgical pleural intervention (p = 0.02). In summary, post-OLT PPEf were associated with increased mortality. Ninety percent of these effusions were exudates by Light's criteria. Defining exudates using LDH only and incorporating cellular analysis, including neutrophils and RBCs, was useful in predicting morbidity.
- Published
- 2023
14. Outcomes and Prognostic Factors of Pulmonary Hypertension Patients Undergoing Emergent Endotracheal Intubation
- Author
-
Hong, Andrew W, Toppen, William, Lee, Joyce, Wilhalme, Holly, Saggar, Rajan, and Barjaktarevic, Igor Z
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Lung ,Clinical Research ,Comparative Effectiveness Research ,Rehabilitation ,Good Health and Well Being ,Adult ,Humans ,Retrospective Studies ,Prognosis ,Intubation ,Intratracheal ,Cohort Studies ,Intensive Care Units ,endotracheal intubation ,pulmonary hypertension ,right heart failure ,critical care ,mechanical ventilation ,vasopressor agents ,acute kidney injury ,Nursing ,Emergency & Critical Care Medicine ,Clinical sciences - Abstract
Background: Emergent endotracheal intubations (ETI) in pulmonary hypertension (PH) patients are associated with increased mortality. Post-intubation interventions that could increase survivability in this population have not been explored. We evaluate early clinical characteristics and complications following emergent endotracheal intubation and seek predictors of adverse outcomes during this post-intubation period. Methods: Retrospective cohort analysis of adult patients with groups 1 and 3 PH who underwent emergent intubation between 2005-2021 in medical and liver transplant ICUs at a tertiary medical center. PH patients were compared to non-PH patients, matched by Charlson Comorbidity Index. Primary outcomes were 24-h post-intubation and inpatient mortalities. Various 24-h post-intubation secondary outcomes were compared between PH and control cohorts. Results: We identified 48 PH and 110 non-PH patients. Pulmonary hypertension was not associated with increased 24-h mortality (OR 1.32, 95%CI 0.35-4.94, P = .18), but was associated with inpatient mortality (OR 4.03, 95%CI 1.29-12.5, P = .016) after intubation. Within 24 h post-intubation, PH patients experienced more frequent acute kidney injury (43.5% vs. 19.8%, P = .006) and required higher norepinephrine dosing equivalents (6.90 [0.13-10.6] mcg/kg/min, vs. 0.20 [0.10-2.03] mcg/kg/min, P = .037). Additionally, the median P/F ratio (PaO2/FiO2) was lower in PH patients (96.3 [58.9-201] vs. 233 [146-346] in non-PH, P = .001). Finally, a post-intubation increase in PaCO2 was associated with mortality in the PH cohort (post-intubation change in PaCO2 +5.14 ± 16.1 in non-survivors vs. -18.7 ± 28.0 in survivors, P = .007). Conclusions: Pulmonary hypertension was associated with worse outcomes after emergent endotracheal intubation than similar patients without PH. More importantly, our data suggest that the first 24 hours following intubation in the PH group represent a particularly vulnerable period that may determine long-term outcomes. Early post-intubation interventions may be key to improving survival in this population.
- Published
- 2023
15. Predicting severe chronic obstructive pulmonary disease exacerbations using quantitative CT: a retrospective model development and external validation study.
- Author
-
Chaudhary, Muhammad, Hoffman, Eric, Guo, Junfeng, Comellas, Alejandro, Newell, John, Nagpal, Prashant, Fortis, Spyridon, Christensen, Gary, Gerard, Sarah, Pan, Yue, Wang, Di, Abtin, Fereidoun, Barjaktarevic, Igor, Barr, R, Bhatt, Surya, Bodduluri, Sandeep, Cooper, Christopher, Gravens-Mueller, Lisa, Han, MeiLan, Kazerooni, Ella, Martinez, Fernando, Menchaca, Martha, Ortega, Victor, Iii, Robert, Schroeder, Joyce, Woodruff, Prescott, and Reinhardt, Joseph
- Subjects
Male ,Humans ,Female ,Middle Aged ,Retrospective Studies ,Quality of Life ,Forced Expiratory Volume ,Pulmonary Disease ,Chronic Obstructive ,Biomarkers ,Tomography ,X-Ray Computed - Abstract
BACKGROUND: Quantitative CT is becoming increasingly common for the characterisation of lung disease; however, its added potential as a clinical tool for predicting severe exacerbations remains understudied. We aimed to develop and validate quantitative CT-based models for predicting severe chronic obstructive pulmonary disease (COPD) exacerbations. METHODS: We analysed the Subpopulations and Intermediate Outcome Measures In COPD Study (SPIROMICS) cohort, a multicentre study done at 12 clinical sites across the USA, of individuals aged 40-80 years from four strata: individuals who never smoked, individuals who smoked but had normal spirometry, individuals who smoked and had mild to moderate COPD, and individuals who smoked and had severe COPD. We used 3-year follow-up data to develop logistic regression classifiers for predicting severe exacerbations. Predictors included age, sex, race, BMI, pulmonary function, exacerbation history, smoking status, respiratory quality of life, and CT-based measures of density gradient texture and airway structure. We externally validated our models in a subset from the Genetic Epidemiology of COPD (COPDGene) cohort. Discriminative model performance was assessed using the area under the receiver operating characteristic curve (AUC), which was also compared with other predictors, including exacerbation history and the BMI, airflow obstruction, dyspnoea, and exercise capacity (BODE) index. We evaluated model calibration using calibration plots and Brier scores. FINDINGS: Participants in SPIROMICS were enrolled between Nov 12, 2010, and July 31, 2015. Participants in COPDGene were enrolled between Jan 10, 2008, and April 15, 2011. We included 1956 participants from the SPIROMICS cohort who had complete 3-year follow-up data: the mean age of the cohort was 63·1 years (SD 9·2) and 1017 (52%) were men and 939 (48%) were women. Among the 1956 participants, 434 (22%) had a history of at least one severe exacerbation. For the CT-based models, the AUC was 0·854 (95% CI 0·852-0·855) for at least one severe exacerbation within 3 years and 0·931 (0·930-0·933) for consistent exacerbations (defined as ≥1 acute episode in each of the 3 years). Models were well calibrated with low Brier scores (0·121 for at least one severe exacerbation; 0·039 for consistent exacerbations). For the prediction of at least one severe event during 3-year follow-up, AUCs were significantly higher with CT biomarkers (0·854 [0·852-0·855]) than exacerbation history (0·823 [0·822-0·825]) and BODE index 0·812 [0·811-0·814]). 6965 participants were included in the external validation cohort, with a mean age of 60·5 years (SD 8·9). In this cohort, AUC for at least one severe exacerbation was 0·768 (0·767-0·769; Brier score 0·088). INTERPRETATION: CT-based prediction models can be used for identification of patients with COPD who are at high risk of severe exacerbations. The newly identified CT biomarkers could potentially enable investigation into underlying disease mechanisms responsible for exacerbations. FUNDING: National Institutes of Health and the National Heart, Lung, and Blood Institute.
- Published
- 2023
16. Ambient Air Pollution Exposure and Sleep Quality in COPD.
- Author
-
Sowho, Mudiaga, Koch, Abigail, Putcha, Nirupama, Woo, Han, Gassett, Amanda, Paulin, Laura, Koehler, Kirsten, Barr, R, Comellas, Alejandro, Cooper, Christopher, Barjaktarevic, Igor, Zeidler, Michelle, Billings, Martha, Bowler, Russell, Han, MeiLan, Kim, Victor, Paine Iii, Robert, Parekh, Trisha, Krishnan, Jerry, Peters, Stephen, Woodruff, Prescott, Baugh, Aaron, Kaufman, Joel, Couper, David, and Hansel, Nadia
- Subjects
air pollution ,copd ,obesity ,sleep quality - Abstract
RATIONALE: Ambient air pollution exposure is associated with respiratory morbidity among individuals with chronic obstructive pulmonary disease (COPD), particularly among those with concomitant obesity. Although people with COPD report high incidence of poor sleep quality, no studies have evaluated the association between air pollution exposure, obesity, and sleep disturbances in COPD. METHODS: We analyzed data collected from current and former smokers with COPD enrolled in the Subpopulations and Intermediate Outcome Measures in COPD -Air Pollution ancillary study (SPIROMICS AIR). Socio-demographics and anthropometric measurements were collected, and 1-year mean historical ambient particulate matter (PM2.5) and ozone concentrations at participants residences were estimated by cohort-specific spatiotemporal modeling. Sleep quality was assessed with the Pittsburgh Sleep Quality Index (PSQI), and regression models were constructed to determine the association of 1-year PM2.5 (1Yr-PM2.5) and 1-year ozone (1Yr-ozone) with the PSQI score, and whether obesity modified the association. RESULTS: In 1308 participants (age: 65.8±7.8 years, 42% women), results of regression analyses suggest that each 10µg/m3 increase in 1Yr-PM2.5 was associated with a 2.1-point increase in PSQI (P=0.03). Obesity modified the association between 1Yr-PM2.5 and PSQI (P=0.03). In obese and overweight participants, a 10µg/m3 increase in 1Yr-PM2.5 was associated with a higher PSQI (4.0 points, P
- Published
- 2023
17. An analysis of the regional heterogeneity in tissue elasticity in lung cancer patients with COPD
- Author
-
Lauria, Michael, Stiehl, Bradley, Santhanam, Anand, O’Connell, Dylan, Naumann, Louise, McNitt-Gray, Michael, Raldow, Ann, Goldin, Jonathan, Barjaktarevic, Igor, and Low, Daniel A
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Clinical Research ,Lung Cancer ,Lung ,Women's Health ,Cancer ,Bioengineering ,Chronic Obstructive Pulmonary Disease ,Biomedical Imaging ,4.1 Discovery and preclinical testing of markers and technologies ,COPD ,elasticity ,lung heterogeneity ,biomechanical properties ,function sparing treatment planning ,Biomedical and clinical sciences ,Health sciences - Abstract
PurposeRecent advancements in obtaining image-based biomarkers from CT images have enabled lung function characterization, which could aid in lung interventional planning. However, the regional heterogeneity in these biomarkers has not been well documented, yet it is critical to several procedures for lung cancer and COPD. The purpose of this paper is to analyze the interlobar and intralobar heterogeneity of tissue elasticity and study their relationship with COPD severity.MethodsWe retrospectively analyzed a set of 23 lung cancer patients for this study, 14 of whom had COPD. For each patient, we employed a 5DCT scanning protocol to obtain end-exhalation and end-inhalation images and semi-automatically segmented the lobes. We calculated tissue elasticity using a biomechanical property estimation model. To obtain a measure of lobar elasticity, we calculated the mean of the voxel-wise elasticity values within each lobe. To analyze interlobar heterogeneity, we defined an index that represented the properties of the least elastic lobe as compared to the rest of the lobes, termed the Elasticity Heterogeneity Index (EHI). An index of 0 indicated total homogeneity, and higher indices indicated higher heterogeneity. Additionally, we measured intralobar heterogeneity by calculating the coefficient of variation of elasticity within each lobe.ResultsThe mean EHI was 0.223 ± 0.183. The mean coefficient of variation of the elasticity distributions was 51.1% ± 16.6%. For mild COPD patients, the interlobar heterogeneity was low compared to the other categories. For moderate-to-severe COPD patients, the interlobar and intralobar heterogeneities were highest, showing significant differences from the other groups.ConclusionWe observed a high level of lung tissue heterogeneity to occur between and within the lobes in all COPD severity cases, especially in moderate-to-severe cases. Heterogeneity results demonstrate the value of a regional, function-guided approach like elasticity for procedures such as surgical decision making and treatment planning.
- Published
- 2023
18. Three-Month Variability of Commonly Evaluated Biomarkers in Clinically Stable COPD.
- Author
-
Park, Seon, Saiphoklang, Narongkorn, Phillips, Jonathan, Wilgus, May-Lin, Tashkin, Donald, Cooper, Christopher, Barjaktarevic, Igor, and Buhr, Russell
- Subjects
COPD ,biomarkers ,repeatability ,stability ,variability ,Female ,Humans ,Male ,Biomarkers ,Bronchitis ,Chronic ,C-Reactive Protein ,Forced Expiratory Volume ,Prospective Studies ,Pulmonary Disease ,Chronic Obstructive ,Quality of Life ,Reproducibility of Results ,Aged - Abstract
INTRODUCTION: Clinical decisions in chronic obstructive pulmonary disease (COPD) treatment often utilize serially assessed physiologic parameters and biomarkers. To better understand the reliability of these tests, we evaluated changes in commonly assessed biomarkers over 3 months in patients with clinically stable COPD. METHODS: We performed an observational prospective cohort study of 89 individuals with clinically stable COPD, defined as no exacerbation history within 3 months of enrollment. Biomarkers included lung function and functional performance status, patient-reported outcomes of symptoms and health status, and blood markers of inflammation. The correlation between testing at baseline and at 3-month follow-up was reported as the intraclass correlation coefficient (ICC). Outliers had significant variability between tests, defined as >1.645 standard deviations between the two measurements. Differences in clinical features between outliers and others were compared. RESULTS: Participants with COPD (n = 89) were 70.5 ± 6.7 years old, 54 (61%) male, had a 40 pack-year smoking history with 24.7% being current smokers, and postbronchodilator forced expiratory volume in one second (FEV1) 62.3 ± 22.7% predicted. The biomarkers with excellent agreement between the initial and the follow-up measurements were FEV1 (ICC = 0.96), Saint Georges Respiratory Questionnaire (SGRQ) (ICC = 0.98), COPD Assessment Test (CAT) (ICC = 0.93) and C-reactive protein (CRP) (ICC = 0.90). By contrast, parameters showing less robust agreement were 6-minute walking distance (ICC = 0.75), eosinophil count (ICC = 0.77), erythrocyte sedimentation rate (ICC = 0.75) and white blood cell count (ICC = 0.48). Individuals with greater variability in biomarkers reported chronic bronchitis more often and had higher baseline SGRQ and CAT scores. CONCLUSION: Our study evaluated the stability of commonly assessed biomarkers in clinically stable COPD and showed excellent agreement between baseline and three-month follow-up values for FEV1, SGRQ, CAT and CRP. Individuals with chronic bronchitis and more symptomatic disease at baseline demonstrated greater variability in 3-month interval biomarkers.
- Published
- 2023
19. Proof-of-concept study of compartmentalized lung ventilation using system for asymmetric flow regulation (SAFR).
- Author
-
Barjaktarevic, Igor, Meyerowitz, Glen, Williams, Onike, Emeruwa, I, and Hoftman, Nir
- Subjects
acute respiratory distress syndrome (ARDS) ,asymmetric lung injury ,compartmentalized lung ventilation ,lung heterogeneity ,system for asymmetric flow regulation - Abstract
Asymmetrical distribution of acute lung injury in mechanically ventilated patients can result in a heterogeneity of gas distribution between different regions, potentially worsening ventilation-perfusion matching. Furthermore, overdistension of healthier, more compliant lung regions can lead to barotrauma and limit the effect of increased PEEP on lung recruitment. We propose a System for Asymmetric Flow Regulation (SAFR) which, combined with a novel double lumen endobronchial tube (DLT) may offer individualized lung ventilation to the left and right lungs, better matching each lungs mechanics and pathophysiology. In this preclinical experimental model, the performance of SAFR on gas distribution in a two-lung simulation system was tested. Our results indicate that SAFR may be a technically feasible and potentially clinically useful although further research is warranted.
- Published
- 2023
20. Association Between HIV and Prevalence and Manifestations of Asthma: Analysis of the Multicenter AIDS Cohort Study and Women's Interagency HIV Study
- Author
-
Drummond, M Bradley, Edmonds, Andrew, Ramirez, Catalina, Stosor, Valentina, Barjaktarevic, Igor Z, Morris, Alison, McCormack, Meredith C, Bhatt, Surya P, Alcaide, Maria L, Cribbs, Sushma K, D'Souza, Gypsyamber, Bhandari, Neha, Kunisaki, Ken M, Huang, Laurence, Kassaye, Seble G, Foronjy, Robert, Sharma, Anjali, Westreich, Daniel J, and Adimora, Adaora A
- Subjects
Public Health ,Biomedical and Clinical Sciences ,Clinical Sciences ,Health Sciences ,Lung ,HIV/AIDS ,Asthma ,Infectious Diseases ,Clinical Research ,7.1 Individual care needs ,Management of diseases and conditions ,Respiratory ,Infection ,Female ,Humans ,Cohort Studies ,Prevalence ,Acquired Immunodeficiency Syndrome ,Retrospective Studies ,HIV Infections ,asthma ,HIV ,lung diseases ,Public Health and Health Services ,Virology ,Clinical sciences ,Epidemiology ,Public health - Abstract
BackgroundThe association between HIV and asthma prevalence and manifestations remains unclear, with few studies including women.SettingA retrospective observational cohort study from the Multicenter AIDS Cohort Study and Women's Interagency HIV Study.MethodsAsthma was defined in 2 ways: (1) self-report and (2) robust criteria requiring all the following: lack of fixed airflow obstruction, presence of wheeze on the St. George's Respiratory Questionnaire (SGRQ), and report of asthma therapies. Estimates of asthma prevalence and asthma-related manifestations were compared by HIV serostatus.ResultsA total of 1815 men and 2122 women were included. Asthma prevalence did not differ between people with HIV (PWH) and people without HIV regardless of definition: self-report (men, 12.0% vs. 11.2%; women, 24.3% vs. 27.5%) and robust criteria (men, 5.0% vs. 3.4%; women, 12.8% vs. 13.2%). Among men with asthma, worse respiratory symptom burden was reported among those with HIV, regardless of asthma definition. Among women with self-reported asthma, those with HIV had less respiratory symptom burden. Regardless of serostatus, women with robust-defined asthma had similar respiratory symptoms across SGRQ domains and similar frequencies of phlegm, shortness of breath, and wheezing.ConclusionsAmong PWH and people without HIV, asthma prevalence was 2-fold to 3-fold higher using self-reported definition rather than robust definition. In men and women, HIV was not associated with increased asthma prevalence. In men, HIV was associated with more respiratory symptoms when asthma was self-reported; the relationship was attenuated with the robust criteria. Further studies are needed to explore asthma phenotypes among PWH.
- Published
- 2022
21. Correlation between Hand Grip Strength and Peak Inspiratory Flow Rate in Patients with Stable Chronic Obstructive Pulmonary Disease.
- Author
-
Suriyakul, Apisara, Saiphoklang, Narongkorn, Barjaktarevic, Igor, and Cooper, Christopher
- Subjects
Accuhaler ,Turbuhaler ,dry powder inhalers ,hand grip strength ,peak inspiratory flow rate - Abstract
Optimal peak inspiratory flow rate (PIFR) is required for effective drug delivery to distal airways when using dry powder inhalers (DPIs). This study aimed to examine the association between PIFR and hand grip strength (HGS) in stable COPD patients. A cross-sectional study was conducted. PIFR was measured using the In-check DIAL to assess for Accuhaler and Turbuhaler DPIs. HGS was measured using a handheld dynamometer. A PIFR of
- Published
- 2022
22. Pulmonary Function Trajectories in People with HIV: Analysis of the Pittsburgh HIV Lung Cohort.
- Author
-
Konstantinidis, Ioannis, Qin, Shulin, Fitzpatrick, Meghan, Kessinger, Cathy, Gentry, Heather, McMahon, Deborah, Weinman, R Dawn, Tien, Phyllis, Huang, Laurence, McCormack, Meredith, Barjaktarevic, Igor, Reddy, Divya, Foronjy, Robert, Lazarous, Deepa, Cohen, Mardge H, McKay, Heather, Adimora, Adaora A, Moran, Caitlin, Fischl, Margaret A, Dionne-Odom, Jodie, Stosor, Valentina, Drummond, M Bradley, Cribbs, Sushma K, Kunisaki, Ken, Rinaldo, Charles, Morris, Alison, and Nouraie, S Mehdi
- Subjects
Medical Microbiology ,Biomedical and Clinical Sciences ,Clinical Research ,Infectious Diseases ,Lung ,HIV/AIDS ,2.4 Surveillance and distribution ,Aetiology ,Respiratory ,Good Health and Well Being ,Humans ,Endothelin-1 ,Forced Expiratory Volume ,Vital Capacity ,Lung Diseases ,HIV Infections ,Dyspnea ,Cytokines ,human immunodeficiency virus ,pulmonary function ,group-based trajectory modeling ,Cardiovascular medicine and haematology ,Clinical sciences - Abstract
Rationale: Human immunodeficiency virus (HIV) infection is associated with chronic lung disease and impaired pulmonary function; however, longitudinal pulmonary function phenotypes in HIV are undefined. Objectives: To identify pulmonary function trajectories, their determinants, and outcomes. Methods: We used data from participants with HIV in the Pittsburgh HIV Lung Cohort with three or more pulmonary function tests between 2007 and 2020. We analyzed post-bronchodilator forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and FEV1/FVC, and diffusing capacity of the lung for carbon monoxide (DlCO) using group-based trajectory modeling to identify subgroups of individuals whose measurements followed a similar pattern over time. We examined the association between participant characteristics and trajectories using multivariable logistic regression. In exploratory adjusted analyses restricted to individuals with available plasma cytokine data, we investigated the association between 18 individual standardized cytokine concentrations and trajectories. We compared mortality, dyspnea prevalence, respiratory health status, and 6-minute-walk distance between phenotypes. Results: A total of 265 participants contributed 1,606 pulmonary function measurements over a median follow-up of 8.1 years. We identified two trajectories each for FEV1 and FVC: "low baseline, slow decline" and "high baseline, rapid decline." There were three trajectory groups for FEV1/FVC: "rapid decline," "moderate decline," and "slow decline." Finally, we identified two trajectories for DlCO: "baseline low" and "baseline high." The low baseline, slow decline FEV1 and FVC, rapid decline, and moderate decline FEV1/FVC, and baseline low DlCO phenotypes were associated with increased dyspnea prevalence, worse respiratory health status, and decreased 6-minute-walk distance. The baseline low DlCO phenotype was also associated with worse mortality. Current smoking and pack-years of smoking were associated with the adverse FEV1, FEV1/FVC, and DlCO phenotypes. Detectable viremia was the only HIV marker associated with the adverse DlCO phenotype. C-reactive protein and endothelin-1 were associated with the adverse FEV1 and FVC phenotypes, and endothelin-1 trended toward an association with the adverse DlCO phenotype. Conclusions: We identified novel, distinct longitudinal pulmonary function phenotypes with significant differences in characteristics and outcomes. These findings highlight the importance of lung dysfunction over time in people with HIV and should be validated in additional cohorts.
- Published
- 2022
23. Bronchodilators in Tobacco-Exposed Persons with Symptoms and Preserved Lung Function
- Author
-
Han, MeiLan K, Ye, Wen, Wang, Di, White, Emily, Arjomandi, Mehrdad, Barjaktarevic, Igor Z, Brown, Stacey-Ann, Buhr, Russell G, Comellas, Alejandro P, Cooper, Christopher B, Criner, Gerard J, Dransfield, Mark T, Drescher, Frank, Folz, Rodney J, Hansel, Nadia N, Kalhan, Ravi, Kaner, Robert J, Kanner, Richard E, Krishnan, Jerry A, Lazarus, Stephen C, Maddipati, Veeranna, Martinez, Fernando J, Mathews, Anne, Meldrum, Catherine, McEvoy, Charlene, Nyunoya, Toru, Rogers, Linda, Stringer, William W, Wendt, Christine H, Wise, Robert A, Wisniewski, Stephen R, Sciurba, Frank C, and Woodruff, Prescott G
- Subjects
Lung ,Tobacco ,Clinical Research ,Clinical Trials and Supportive Activities ,Tobacco Smoke and Health ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Respiratory ,Good Health and Well Being ,Adrenergic beta-2 Receptor Agonists ,Anti-Bacterial Agents ,Bronchodilator Agents ,Forced Expiratory Volume ,Glucocorticoids ,Glycopyrrolate ,Humans ,Pulmonary Disease ,Chronic Obstructive ,Treatment Outcome ,RETHINC Study Group ,Medical and Health Sciences ,General & Internal Medicine - Abstract
BackgroundMany persons with a history of smoking tobacco have clinically significant respiratory symptoms despite an absence of airflow obstruction as assessed by spirometry. They are often treated with medications for chronic obstructive pulmonary disease (COPD), but supporting evidence for this treatment is lacking.MethodsWe randomly assigned persons who had a tobacco-smoking history of at least 10 pack-years, respiratory symptoms as defined by a COPD Assessment Test score of at least 10 (scores range from 0 to 40, with higher scores indicating worse symptoms), and preserved lung function on spirometry (ratio of forced expiratory volume in 1 second [FEV1] to forced vital capacity [FVC] ≥0.70 and FVC ≥70% of the predicted value after bronchodilator use) to receive either indacaterol (27.5 μg) plus glycopyrrolate (15.6 μg) or placebo twice daily for 12 weeks. The primary outcome was at least a 4-point decrease (i.e., improvement) in the St. George's Respiratory Questionnaire (SGRQ) score (scores range from 0 to 100, with higher scores indicating worse health status) after 12 weeks without treatment failure (defined as an increase in lower respiratory symptoms treated with a long-acting inhaled bronchodilator, glucocorticoid, or antibiotic agent).ResultsA total of 535 participants underwent randomization. In the modified intention-to-treat population (471 participants), 128 of 227 participants (56.4%) in the treatment group and 144 of 244 (59.0%) in the placebo group had at least a 4-point decrease in the SGRQ score (difference, -2.6 percentage points; 95% confidence interval [CI], -11.6 to 6.3; adjusted odds ratio, 0.91; 95% CI, 0.60 to 1.37; P = 0.65). The mean change in the percent of predicted FEV1 was 2.48 percentage points (95% CI, 1.49 to 3.47) in the treatment group and -0.09 percentage points (95% CI, -1.06 to 0.89) in the placebo group, and the mean change in the inspiratory capacity was 0.12 liters (95% CI, 0.07 to 0.18) in the treatment group and 0.02 liters (95% CI, -0.03 to 0.08) in the placebo group. Four serious adverse events occurred in the treatment group, and 11 occurred in the placebo group; none were deemed potentially related to the treatment or placebo.ConclusionsInhaled dual bronchodilator therapy did not decrease respiratory symptoms in symptomatic, tobacco-exposed persons with preserved lung function as assessed by spirometry. (Funded by the National Heart, Lung, and Blood Institute and others; RETHINC ClinicalTrials.gov number, NCT02867761.).
- Published
- 2022
24. Reversible Airflow Obstruction Predicts Future Chronic Obstructive Pulmonary Disease Development in the SPIROMICS Cohort: An Observational Cohort Study.
- Author
-
Han, MeiLan, Hansel, Nadia, Krishnan, Jerry, Martinez, Fernando, McKleroy, William, Paine, Robert, Rennard, Stephen, Tashkin, Donald, Woodruff, Prescott, Kanner, Richard, Barjaktarevic, Igor, Quibrera, P, Bateman, Lori, Bleecker, Eugene, Couper, David, Curtis, Jeffrey, Cooper, Christopher, Buhr, Russell, and Dolezal, Brett
- Subjects
COPD ,multilevel modeling ,pulmonary physiology ,spirometry ,survival analysis ,Airway Obstruction ,Asthma ,Bronchodilator Agents ,Cohort Studies ,Forced Expiratory Volume ,Humans ,Pulmonary Disease ,Chronic Obstructive ,Spirometry ,Vital Capacity - Abstract
Rationale: Chronic obstructive pulmonary disease (COPD) is defined by fixed spirometric ratio, FEV1/FVC
- Published
- 2022
25. Risk of COPD exacerbation is increased by poor sleep quality and modified by social adversity.
- Author
-
Baugh, Aaron, Buhr, Russell G, Quibrera, Pedro, Barjaktarevic, Igor, Barr, R Graham, Bowler, Russell, Han, Meilan King, Kaufman, Joel D, Koch, Abigail L, Krishnan, Jerry, Labaki, Wassim, Martinez, Fernando J, Mkorombindo, Takudzwa, Namen, Andrew, Ortega, Victor, Paine, Robert, Peters, Stephen P, Schotland, Helena, Sundar, Krishna, Zeidler, Michelle R, Hansel, Nadia N, Woodruff, Prescott G, and Thakur, Neeta
- Subjects
Sleep Research ,Chronic Obstructive Pulmonary Disease ,Lung ,Behavioral and Social Science ,Respiratory ,Good Health and Well Being ,Disease Progression ,Humans ,Pulmonary Disease ,Chronic Obstructive ,Severity of Illness Index ,Sleep Quality ,Sleep Wake Disorders ,sleep quality ,PSQI ,exacerbations ,COPD ,health disparities ,Biological Sciences ,Medical and Health Sciences ,Psychology and Cognitive Sciences ,Neurology & Neurosurgery - Abstract
Study objectivesSleep is an important dimension in the care of chronic obstructive pulmonary disease (COPD), but its relevance to exacerbations is unclear. We wanted to assess whether sleep quality as measured by the Pittsburgh Sleep Quality Index (PSQI) is associated with an increased risk of COPD exacerbations and does this differ by socio-environmental exposures.MethodsWe included 1647 current and former smokers with spirometrically confirmed COPD from the SPIROMICS cohort. We assessed incidence rate ratios for exacerbation using zero-inflated negative binomial regression adjusting for demographics, medical comorbidities, and multiple metrics of disease severity, including respiratory medications, airflow obstruction, and symptom burden. Our final model adjusted for socio-environmental exposures using the Area Deprivation Index, a composite measure of contemporary neighborhood quality, and Adversity-Opportunity Index, a composite measure of individual-level historic and current socioeconomic indicators. We used a pre-determined threshold of 20% missingness to undertake multiple imputation by chained equations. As sensitivity analyses, we repeated models in those with complete data and after controlling for prior exacerbations. As an exploratory analysis, we considered an interaction between socio-environmental condition and sleep quality.ResultsAfter adjustment for all co-variates, increasing PSQI scores (range 0-21) were associated with a 5% increased risk for exacerbation per point (p = .001) in the imputed dataset. Sensitivity analyses using complete cases and after controlling for prior exacerbation history were similar. Exploratory analysis suggested less effect among those who lived in poor-quality neighborhoods (p-for-interaction = .035).ConclusionsPoor sleep quality may contribute to future exacerbations among patients with COPD. This represents one target for improving disease control.Clinical trial registrationSubpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS). ClinicalTrials.gov Identifier# NCT01969344. Registry URL: https://clinicaltrials.gov/ct2/show/.
- Published
- 2022
26. Association of bronchial disease on CT imaging and clinical definitions of chronic bronchitis in a single-center COPD phenotyping study
- Author
-
Fat, Marisa, Andersen, Tyler, Fazio, Jane C., Park, Seon Cheol, Abtin, Fereidoun, Buhr, Russell G., Phillips, Jonathan E., Belperio, John, Tashkin, Donald P., Cooper, Christopher B., and Barjaktarevic, Igor
- Published
- 2024
- Full Text
- View/download PDF
27. Estimating ambient air pollutant concentrations outside and inside homes in the Subpopulations and Intermediate outcomes in COPD air pollution (SPIROMICS air) cohort
- Author
-
Kirwa, Kipruto, Gassett, Amanda J., Sack, Coralynn, Paulin, Laura M., Pirozzi, Cheryl S., Barr, R. Graham, Woodruff, Prescott G., Han, MeiLan, Wilgus, May-Lin, Barjaktarevic, Igor, Peters, Stephen, Hansel, Nadia N., and Kaufman, Joel D.
- Published
- 2024
- Full Text
- View/download PDF
28. Predictors of Invasiveness in Adenocarcinoma of Lung with Lepidic Growth Pattern.
- Author
-
Young, Timothy J, Salehi-Rad, Ramin, Ronaghi, Reza, Yanagawa, Jane, Shahrouki, Puja, Villegas, Bianca E, Cone, Brian, Fishbein, Gregory A, Wallace, William D, Abtin, Fereidoun, and Barjaktarevic, Igor
- Subjects
Lung ,Humans ,Adenocarcinoma ,Lung Neoplasms ,Neoplasm Invasiveness ,Neoplasm Staging ,Adenocarcinoma in Situ ,Adenocarcinoma of Lung ,adenocarcinoma in situ ,ground-glass ,lepidic pattern ,lung biopsy ,lung cancer ,Lung Cancer ,Rare Diseases ,Cancer ,Clinical Research ,4.2 Evaluation of markers and technologies ,Detection ,screening and diagnosis - Abstract
Lung adenocarcinoma with lepidic growth pattern (LPA) is characterized by tumor cell proliferation along intact alveolar walls, and further classified as adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma (MIA) and invasive lepidic predominant adenocarcinoma (iLPA). Accurate diagnosis of lepidic lesions is critical for appropriate prognostication and management as five-year survival in patients with iLPA is lower than in those with AIS and MIA. We aimed to evaluate the accuracy of CT-guided core needle lung biopsy classifying LPA lesions and identify clinical and radiologic predictors of invasive disease in biopsied lesions. Thirty-four cases of adenocarcinoma with non-invasive lepidic growth pattern on core biopsy pathology that subsequently were resected between 2011 and 2018 were identified. Invasive LPA vs. non-invasive LPA (AIS or MIA) was defined based on explant pathology. Histopathology of core biopsy and resected tumor specimens was compared for concordance, and clinical, radiologic and pathologic variables were analyzed to assess for correlation with invasive disease. The majority of explanted tumors (70.6%) revealed invasive disease. Asian race (p = 0.03), history of extrathoracic malignancy (p = 0.02) and absence of smoking history (p = 0.03) were associated with invasive disease. CT-measured tumor size was not associated with invasiveness (p = 0.15). CT appearance of density (p = 0.61), shape (p = 0.78), and margin (p = 0.24) did not demonstrate a significant difference between the two subgroups. Invasiveness of tumors with lepidic growth patterns can be underestimated on transthoracic core needle biopsies. Asian race, absence of smoking, and history of extrathoracic malignancy were associated with invasive disease.
- Published
- 2022
29. Fazirsiran for Adults With Alpha-1 Antitrypsin Deficiency Liver Disease: A Phase 2 Placebo Controlled Trial (SEQUOIA)
- Author
-
Clark, Virginia C., Strange, Charlie, Strnad, Pavel, Sanchez, Antonio J., Kwo, Paul, Pereira, Vitor Magno, van Hoek, Bart, Barjaktarevic, Igor, Corsico, Angelo Guido, Pons, Monica, Goldklang, Monica, Gray, Meagan, Kuhn, Brooks, Vargas, Hugo E., Vierling, John M., Vuppalanchi, Raj, Brantly, Mark, Kappe, Naomi, Chang, Ting, Schluep, Thomas, Zhou, Rong, Hamilton, James, San Martin, Javier, and Loomba, Rohit
- Published
- 2024
- Full Text
- View/download PDF
30. Identification of Sputum Biomarkers Predictive of Pulmonary Exacerbations in COPD
- Author
-
Esther, Charles R, O’Neal, Wanda K, Anderson, Wayne H, Kesimer, Mehmet, Ceppe, Agathe, Doerschuk, Claire M, Alexis, Neil E, Hastie, Annette T, Barr, R Graham, Bowler, Russell P, Wells, J Michael, Oelsner, Elizabeth C, Comellas, Alejandro P, Tesfaigzi, Yohannes, Kim, Victor, Paulin, Laura M, Cooper, Christopher B, Han, MeiLan K, Huang, Yvonne J, Labaki, Wassim W, Curtis, Jeffrey L, Boucher, Richard C, Study, Subpopulations and Intermediate Outcome Measures in COPD, Arjomandi, Mehrdad, Barjaktarevic, Igor, Bateman, Lori A, Bhatt, Surya P, Bleecker, Eugene R, Christenson, Stephanie A, Couper, David J, Criner, Gerard J, Crystal, Ronald G, Dransfield, Mark T, Drummond, Brad, Freeman, Christine M, Galban, Craig, Hansel, Nadia N, Hoffman, Eric A, Huang, Yvonne, Kaner, Robert J, Kanner, Richard E, Kleerup, Eric C, Krishnan, Jerry A, LaVange, Lisa M, Lazarus, Stephen C, Martinez, Fernando J, Meyers, Deborah A, Moore, Wendy C, Newell, John D, Paine, Robert, Paulin, Laura, Peters, Stephen P, Pirozzi, Cheryl, Putcha, Nirupama, Ortega, Victor E, Raman, Sanjeev, Rennard, Stephen I, Tashkin, Donald P, Wise, Robert A, and Woodruff, Prescott G
- Subjects
Lung ,Chronic Obstructive Pulmonary Disease ,Clinical Research ,Respiratory ,Good Health and Well Being ,Biomarkers ,Humans ,Hypoxanthines ,N-Acetylneuraminic Acid ,Pulmonary Disease ,Chronic Obstructive ,Sputum ,adenosine ,glutathione ,inflammation ,metabolomics ,methionine salvage ,mucus ,Subpopulations and Intermediate Outcome Measures in COPD Study ,Clinical Sciences ,Respiratory System - Abstract
BackgroundImproved understanding of the pathways associated with airway pathophysiologic features in COPD will identify new predictive biomarkers and novel therapeutic targets.Research questionWhich physiologic pathways are altered in the airways of patients with COPD and will predict exacerbations?Study design and methodsWe applied a mass spectrometric panel of metabolomic biomarkers related to mucus hydration and inflammation to sputa from the multicenter Subpopulations and Intermediate Outcome Measures in COPD Study. Biomarkers elevated in sputa from patients with COPD were evaluated for relationships to measures of COPD disease severity and their ability to predict future exacerbations.ResultsSputum supernatants from 980 patients were analyzed: 77 healthy nonsmokers, 341 smokers with preserved spirometry, and 562 patients with COPD (178 with Global Initiative on Chronic Obstructive Lung Disease [GOLD] stage 1 disease, 303 with GOLD stage 2 disease, and 81 with GOLD stage 3 disease) were analyzed. Biomarkers from multiple pathways were elevated in COPD and correlated with sputum neutrophil counts. Among the most significant analytes (false discovery rate, 0.1) were sialic acid, hypoxanthine, xanthine, methylthioadenosine, adenine, and glutathione. Sialic acid and hypoxanthine were associated strongly with measures of disease severity, and elevation of these biomarkers was associated with shorter time to exacerbation and improved prediction models of future exacerbations.InterpretationBiomarker evaluation implicated pathways involved in mucus hydration, adenosine metabolism, methionine salvage, and oxidative stress in COPD airway pathophysiologic characteristics. Therapies that target these pathways may be of benefit in COPD, and a simple model adding sputum-soluble phase biomarkers improves prediction of pulmonary exacerbations.Trial registryClinicalTrials.gov; No.: NCT01969344; URL: www.Clinicaltrialsgov.
- Published
- 2022
31. Forced Expiratory Flow at 25%-75% Links COPD Physiology to Emphysema and Disease Severity in the SPIROMICS Cohort.
- Author
-
Ronish, Bonnie E, Couper, David J, Barjaktarevic, Igor Z, Cooper, Christopher B, Kanner, Richard E, Pirozzi, Cheryl S, Kim, Victor, Wells, James M, Han, MeiLan K, Woodruff, Prescott G, Ortega, Victor E, Peters, Stephen P, Hoffman, Eric A, Buhr, Russell G, Dolezal, Brett A, Tashkin, Donald P, Liou, Theodore G, Bateman, Lori A, Schroeder, Joyce D, Martinez, Fernando J, Barr, R Graham, Hansel, Nadia N, Comellas, Alejandro P, Rennard, Stephen I, Arjomandi, Mehrdad, and Paine Iii, Robert
- Subjects
Epidemiology ,Biomedical and Clinical Sciences ,Health Sciences ,Clinical Research ,Lung ,Emphysema ,Chronic Obstructive Pulmonary Disease ,Respiratory ,spirometry ,pulmonary physiology ,emphysema ,FEF25-75% ,mid-flow rate ,functional small airways disease - Abstract
BackgroundForced expiratory volume in 1 second (FEV1) is central to the diagnosis of chronic obstructive pulmonary disease (COPD) but is imprecise in classifying disease burden. We examined the potential of the maximal mid-expiratory flow rate (forced expiratory flow rate between 25% and 75% [FEF25%-75%]) as an additional tool for characterizing pathophysiology in COPD.ObjectiveTo determine whether FEF25%-75% helps predict clinical and radiographic abnormalities in COPD.Study design and methodsThe SubPopulations and InteRediate Outcome Measures In COPD Study (SPIROMICS) enrolled a prospective cohort of 2978 nonsmokers and ever-smokers, with and without COPD, to identify phenotypes and intermediate markers of disease progression. We used baseline data from 2771 ever-smokers from the SPIROMICS cohort to identify associations between percent predicted FEF25%-75% (%predFEF25%-75%) and both clinical markers and computed tomography (CT) findings of smoking-related lung disease.ResultsLower %predFEF25-75% was associated with more severe disease, manifested radiographically by increased functional small airways disease, emphysema (most notably with homogeneous distribution), CT-measured residual volume, total lung capacity (TLC), and airway wall thickness, and clinically by increased symptoms, decreased 6-minute walk distance, and increased bronchodilator responsiveness (BDR). A lower %predFEF25-75% remained significantly associated with increased emphysema, functional small airways disease, TLC, and BDR after adjustment for FEV1 or forced vital capacity (FVC).InterpretationThe %predFEF25-75% provides additional information about disease manifestation beyond FEV1. These associations may reflect loss of elastic recoil and air trapping from emphysema and intrinsic small airways disease. Thus, %predFEF25-75% helps link the anatomic pathology and deranged physiology of COPD.
- Published
- 2022
32. A Metabolomic Severity Score for Airflow Obstruction and Emphysema.
- Author
-
Godbole, Suneeta, Labaki, Wassim, Pratte, Katherine, Hill, Andrew, Moll, Matthew, Hastie, Annette, Peters, Stephen, Gregory, Andrew, Ortega, Victor, DeMeo, Dawn, Cho, Michael, Bhatt, Surya, Wells, J, Barjaktarevic, Igor, Stringer, Kathleen, Comellas, Alejandro, ONeal, Wanda, Kechris, Katerina, and Bowler, Russell
- Subjects
COPD ,adaptive LASSO ,lung density ,metabolomics - Abstract
Chronic obstructive pulmonary disease (COPD) is a disease with marked metabolic disturbance. Previous studies have shown the association between single metabolites and lung function for COPD, but whether a combination of metabolites could predict phenotype is unknown. We developed metabolomic severity scores using plasma metabolomics from the Metabolon platform from two US cohorts of ever-smokers: the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS) (n = 648; training/testing cohort; 72% non-Hispanic, white; average age 63 years) and the COPDGene Study (n = 1120; validation cohort; 92% non-Hispanic, white; average age 67 years). Separate adaptive LASSO (adaLASSO) models were used to model forced expiratory volume at one second (FEV1) and MESA-adjusted lung density using 762 metabolites common between studies. Metabolite coefficients selected by the adaLASSO procedure were used to create a metabolomic severity score (metSS) for each outcome. A total of 132 metabolites were selected to create a metSS for FEV1. The metSS-only models explained 64.8% and 31.7% of the variability in FEV1 in the training and validation cohorts, respectively. For MESA-adjusted lung density, 129 metabolites were selected, and metSS-only models explained 59.0% of the variability in the training cohort and 17.4% in the validation cohort. Regression models including both clinical covariates and the metSS explained more variability than either the clinical covariate or metSS-only models (53.4% vs. 46.4% and 31.6%) in the validation dataset. The metabolomic pathways for arginine biosynthesis; aminoacyl-tRNA biosynthesis; and glycine, serine, and threonine pathway were enriched by adaLASSO metabolites for FEV1. This is the first demonstration of a respiratory metabolomic severity score, which shows how a metSS can add explanation of variance to clinical predictors of FEV1 and MESA-adjusted lung density. The advantage of a comprehensive metSS is that it explains more disease than individual metabolites and can account for substantial collinearity among classes of metabolites. Future studies should be performed to determine whether metSSs are similar in younger, and more racially and ethnically diverse populations as well as whether a metabolomic severity score can predict disease development in individuals who do not yet have COPD.
- Published
- 2022
33. Significance of FEV3/FEV6 in Recognition of Early Airway Disease in Smokers at Risk of Development of COPD Analysis of the SPIROMICS Cohort
- Author
-
Yee, Nathan, Markovic, Daniela, Buhr, Russell G, Fortis, Spyridon, Arjomandi, Mehrdad, Couper, David, Anderson, Wayne H, Paine, Robert, Woodruff, Prescott G, Han, Meilan K, Martinez, Fernando J, Barr, R Graham, Wells, James M, Ortega, Victor E, Hoffman, Eric A, Kim, Victor, Drummond, M Bradley, Bowler, Russell P, Curtis, Jeffrey L, Cooper, Christopher B, Tashkin, Donald P, and Barjaktarevic, Igor Z
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Clinical Sciences ,Chronic Obstructive Pulmonary Disease ,Clinical Research ,Lung ,Respiratory ,Bronchodilator Agents ,Forced Expiratory Volume ,Humans ,Pulmonary Disease ,Chronic Obstructive ,Respiration Disorders ,Smokers ,Spirometry ,Vital Capacity ,COPD ,early airflow obstruction ,small airways disease ,spirometry ,FEV3 ,FEV6 ,FEV3/FEV6 ,FEV(3) ,FEV(3)/FEV(6) ,FEV(6) ,Respiratory System ,Cardiovascular medicine and haematology ,Clinical sciences - Abstract
BackgroundSmall airways are known to be affected early in the course of COPD; however, traditional spirometric indices may not accurately identify small airways disease.Research questionCan forced expiratory volume in 3 s/forced expiratory volume in 6 s (FEV3/FEV6) identify early airflow abnormalities and predict future clinically important respiratory-related outcomes, including development of COPD?Study design and methodsThe study included 832 current and former smokers with post-bronchodilator FEV1/FVC ≥ 0.7 from the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS) cohort. Participants were classified as having a reduced pre-bronchodilator FEV3/FEV6 based on lower limit of normal (LLN) values. Repeatability analysis was performed for FEV3 and FEV6. Regression modeling was used to evaluate the relationship between baseline FEV3/FEV6 and outcome measures, including functional small airways disease, on thoracic imaging and respiratory exacerbations. Interval-censored analysis was used to assess progression to COPD.ResultsFEV3/FEV6 less than the LLN at baseline, defined as reduced compared with FEV3/FEV6 at or above the LLN, was associated with lower FEV1, poorer health status (St. George's Respiratory Questionnaire score), more emphysema, and more functional small airways disease on quantitative imaging. FEV3 and FEV6 showed excellent agreement between repeat measurements. A reduced FEV3/FEV6 was associated with increased odds of a severe respiratory exacerbation within the first year of follow-up and decreased time to first exacerbation. A low FEV3/FEV6 was also associated with development of COPD according to spirometry results (post-bronchodilator FEV1/FVC < 0.7) during study follow-up.InterpretationFEV3/FEV6 is a routinely available and repeatable spirometric index that can be useful in the evaluation of early airflow obstruction in current and former smokers without COPD. A reduced FEV3/FEV6 can identify those at risk for future development of COPD and respiratory exacerbations.Clinical trial registrationClinicalTrials.gov; No.: NCT01969344; URL: www.Clinicaltrialsgov: ClinicalTrials.gov.
- Published
- 2022
34. Reconsidering the Utility of Race-Specific Lung Function Prediction Equations.
- Author
-
Baugh, Aaron D, Shiboski, Stephen, Hansel, Nadia N, Ortega, Victor, Barjaktarevic, Igor, Barr, R Graham, Bowler, Russell, Comellas, Alejandro P, Cooper, Christopher B, Couper, David, Criner, Gerard, Curtis, Jeffrey L, Dransfield, Mark, Ejike, Chinedu, Han, MeiLan K, Hoffman, Eric, Krishnan, Jamuna, Krishnan, Jerry A, Mannino, David, Paine, Robert, Parekh, Trisha, Peters, Stephen, Putcha, Nirupama, Rennard, Stephen, Thakur, Neeta, and Woodruff, Prescott G
- Subjects
Paediatrics ,Biomedical and Clinical Sciences ,Lung ,Clinical Research ,Chronic Obstructive Pulmonary Disease ,Respiratory ,Forced Expiratory Volume ,Humans ,Pulmonary Disease ,Chronic Obstructive ,Pulmonary Emphysema ,Respiratory Function Tests ,Vital Capacity ,respiratory function tests ,racism ,chronic obstructive pulmonary disease ,health disparities ,Medical and Health Sciences ,Respiratory System ,Cardiovascular medicine and haematology ,Clinical sciences - Abstract
Rationale: African American individuals have worse outcomes in chronic obstructive pulmonary disease (COPD). Objectives: To assess whether race-specific approaches for estimating lung function contribute to racial inequities by failing to recognize pathological decrements and considering them normal. Methods: In a cohort with and at risk for COPD, we assessed whether lung function prediction equations applied in a race-specific versus universal manner better modeled the relationship between FEV1, FVC, and other COPD outcomes, including the COPD Assessment Test, St. George's Respiratory Questionnaire, computed tomography percent emphysema, airway wall thickness, and 6-minute-walk test. We related these outcomes to differences in FEV1 using multiple linear regression and compared predictive performance between fitted models using root mean squared error and Alpaydin's paired F test. Measurements and Main Results: Using race-specific equations, African American individuals were calculated to have better lung function than non-Hispanic White individuals (FEV1, 76.8% vs. 71.8% predicted; P = 0.02). Using universally applied equations, African American individuals were calculated to have worse lung function. Using Hankinson's Non-Hispanic White equation, FEV1 was 64.7% versus 71.8% (P
- Published
- 2022
35. A blood and bronchoalveolar lavage protein signature of rapid FEV1 decline in smoking-associated COPD
- Author
-
DiLillo, Katarina M., Norman, Katy C., Freeman, Christine M., Christenson, Stephanie A., Alexis, Neil E., Anderson, Wayne H., Barjaktarevic, Igor Z., Barr, R. Graham, Comellas, Alejandro P., Bleecker, Eugene R., Boucher, Richard C., Couper, David J., Criner, Gerard J., Doerschuk, Claire M., Wells, J. Michael, Han, MeiLan K., Hoffman, Eric A., Hansel, Nadia N., Hastie, Annette T., Kaner, Robert J., Krishnan, Jerry A., Labaki, Wassim W., Martinez, Fernando J., Meyers, Deborah A., O’Neal, Wanda K., Ortega, Victor E., Paine, III, Robert, Peters, Stephen P., Woodruff, Prescott G., Cooper, Christopher B., Bowler, Russell P., Curtis, Jeffrey L., and Arnold, Kelly B.
- Published
- 2023
- Full Text
- View/download PDF
36. Use of a Wearable Biosensor to Study Heart Rate Variability in Chronic Obstructive Pulmonary Disease and Its Relationship to Disease Severity.
- Author
-
Park, Seon-Cheol, Saiphoklang, Narongkorn, Jung, Donghyun, Gomez, David, Phillips, Jonathan, Dolezal, Brett, Tashkin, Donald, Barjaktarevic, Igor, and Cooper, Christopher
- Subjects
bronchodilator ,chronic obstructive pulmonary disease ,health ,heart rate variability ,wearable sensors ,Biosensing Techniques ,Hand Strength ,Heart Rate ,Humans ,Pulmonary Disease ,Chronic Obstructive ,Severity of Illness Index ,Wearable Electronic Devices - Abstract
The purpose of this study was to explore the relationships between heart rate variability (HRV) and various phenotypic measures that relate to health and functional status in chronic obstructive pulmonary disease (COPD), and secondly, to demonstrate the feasibility of ascertaining HRV via a chest-worn wearable biosensor in COPD patients. HRV analysis was performed using SDNN (standard deviation of the mean of all normal R-R intervals), low frequency (LF), high frequency (HF), and LF/HF ratio. We evaluated the associations between HRV and COPD severity, class of bronchodilator therapy prescribed, and patient reported outcomes. Seventy-nine participants with COPD were enrolled. There were no differences in SDNN, HF, and LF/HF ratio according to COPD severity. The SDNN in participants treated with concurrent beta-agonists and muscarinic antagonists was lower than that in other participants after adjusting heart rate (beta coefficient -3.980, p = 0.019). The SDNN was positively correlated with Veterans Specific Activity Questionnaire (VSAQ) score (r = 0.308, p = 0.006) and handgrip strength (r = 0.285, p = 0.011), and negatively correlated with dyspnea by modified Medical Research Council (mMRC) questionnaire (r = -0.234, p = 0.039), health status by Saint Georges Respiratory Questionnaire (SGRQ) (r = -0.298, p = 0.008), symptoms by COPD Assessment Test (CAT) (r = -0.280, p = 0.012), and BODE index (r = -0.269, p = 0.020). When measured by a chest-worn wearable device, reduced HRV was observed in COPD participants receiving inhaled beta-sympathomimetic agonist and muscarinic antagonists. HRV was also correlated with various health status and performance measures.
- Published
- 2022
37. Comparative Impact of Depressive Symptoms and FEV1% on Chronic Obstructive Pulmonary Disease.
- Author
-
O’Toole, Jacqueline, Woo, Han, Putcha, Nirupama, Cooper, Christopher B, Woodruff, Prescott, Kanner, Richard E, Paine, Robert, Bowler, Russell P, Comellas, Alejandro, Hoth, Karin F, Krishnan, Jerry A, Han, Meilan, Dransfield, Mark, Iyer, Anand S, Couper, David, Peters, Stephen P, Criner, Gerard, Kim, Victor, Barr, R Graham, Martinez, Fernando J, Hansel, Nadia N, Eakin, Michelle N, Alexis, Neil E, Anderson, Wayne H, Arjomandi, Mehrdad, Barjaktarevic, Igor, Bateman, Lori A, Bhatt, Surya P, Bleecker, Eugene R, Boucher, Richard C, Christenson, Stephanie A, Comellas, Alejandro P, Couper, David J, Criner, Gerard J, Crystal, Ronald G, Curtis, Jeffrey L, Doerschuk, Claire M, Dransfield, Mark T, Drummond, Brad, Freeman, Christine M, Galban, Craig, Han, MeiLan K, Hastie, Annette T, Hoffman, Eric A, Huang, Yvonne, Kaner, Robert J, Kleerup, Eric C, LaVange, Lisa M, Lazarus, Stephen C, Meyers, Deborah A, Moore, Wendy C, Newell, John D, Paulin, Laura, Pirozzi, Cheryl, Oelsner, Elizabeth C, O’Neal, Wanda K, Ortega, Victor E, Raman, Sanjeev, Rennard, Stephen I, Tashkin, Donald P, Wells, J Michael, Wise, Robert A, and Woodruff, Prescott G
- Subjects
Clinical Research ,Behavioral and Social Science ,Depression ,Chronic Obstructive Pulmonary Disease ,Mental Health ,Lung ,Respiratory ,Good Health and Well Being ,Female ,Forced Expiratory Volume ,Humans ,Pulmonary Disease ,Chronic Obstructive ,Quality of Life ,Respiratory Function Tests ,Smoking ,Surveys and Questionnaires ,depression ,COPD ,patient reported outcome measures ,SPIROMICS Investigators - Abstract
Rationale: Individuals with chronic obstructive pulmonary disease (COPD) have a high prevalence of depression, which is associated with increased COPD hospitalizations and readmissions. Objectives: Examine the impact of depressive symptoms compared with FEV1% on COPD morbidity. Methods: Using longitudinal data from individuals with COPD in the Subpopulations and Intermediate Outcome Measures in COPD Study, longitudinal growth analysis was performed to assess COPD morbidity by assessing differences in baseline 6-minute walk distance and patient reported outcomes (PROs) and their rate of change over time explained by depressive symptoms or lung function, as measured by Hospital Anxiety and Depression Scale or FEV1% respectively. PROs consisted of in-person completion of St. George's Respiratory Questionnaire, COPD Assessment Test, Functional Assessment of Chronic Illness Therapy Fatigue, and Modified Medical Research Council Dyspnea Scale measures. Results: Of the individuals analyzed (n = 1,830), 43% were female, 81% Caucasian with mean ± SD age of 65.1 ± 8.1, and 52.7 ± 27.5 pack-years smoking. Mean ± SD FEV1% was 60.9 ± 23.0% and 20% had clinically significant depressive symptoms. Adjusted models showed higher Hospital Anxiety and Depression Scale scores and lower FEV1% each were associated with worse PROs at baseline (P ⩽ 0.001). Depression accounted for more baseline variance in St. George's Respiratory Questionnaire, COPD Assessment Test, and Functional Assessment of Chronic Illness Therapy Fatigue than FEV1%, explaining 30-67% of heterogeneity. FEV1% accounted for more baseline variance in Modified Medical Research Council Dyspnea Scale and 6-minute walk distance than depression, explaining 16-32% of heterogeneity. Depressive symptoms accounted for 3-17% variance in change over time in PROs. In contrast, FEV1% accounted for 1-4% variance over time in PROs. Conclusions: Depression is more strongly associated with many PROs at baseline and their change over time compared with FEV1%. Recognizing and incorporating the impact of depressive symptoms into individualized care may improve COPD outcomes.
- Published
- 2022
38. Carotid artery velocity time integral and corrected flow time measured by a wearable Doppler ultrasound detect stroke volume rise from simulated hemorrhage to transfusion.
- Author
-
Kenny, Jon-Émile, Barjaktarevic, Igor, Mackenzie, David, Elfarnawany, Mai, Yang, Zhen, Eibl, Andrew, Eibl, Joseph, Kim, Chul-Ho, and Johnson, Bruce
- Subjects
Carotid Doppler ,Corrected flow time ,Stroke volume ,Velocity time integral ,Blood Flow Velocity ,Carotid Arteries ,Carotid Artery ,Common ,Hemorrhage ,Humans ,Stroke Volume ,Ultrasonography ,Doppler ,Wearable Electronic Devices - Abstract
OBJECTIVE: Doppler ultrasonography of the common carotid artery is used to infer stroke volume change and a wearable Doppler ultrasound has been designed to improve this workflow. Previously, in a human model of hemorrhage and resuscitation comprising approximately 50,000 cardiac cycles, we found a strong, linear correlation between changing stroke volume, and measures from the carotid Doppler signal, however, optimal Doppler thresholds for detecting a 10% stroke volume change were not reported. In this Research Note, we present these thresholds, their sensitivities, specificities and areas under their receiver operator curves (AUROC). RESULTS: Augmentation of carotid artery maximum velocity time integral and corrected flowtime by 18% and 4%, respectively, accurately captured 10% stroke volume rise. The sensitivity and specificity for these thresholds were identical at 89% and 100%. These data are similar to previous investigations in healthy volunteers monitored by the wearable ultrasound.
- Published
- 2022
39. Temporal concordance between pulse contour analysis, bioreactance and carotid doppler during rapid preload changes.
- Author
-
Kenny, Jon-Émile, Barjaktarevic, Igor, Eibl, Andrew, Parrotta, Matthew, Long, Bradley, Elfarnawany, Mai, and Eibl, Joseph
- Subjects
Hemodynamic Monitoring ,Hemodynamics ,Humans ,Monitoring ,Physiologic ,Stroke Volume ,Ultrasonography ,Doppler - Abstract
PURPOSE: We describe the temporal concordance of 3 hemodynamic monitors. MATERIALS AND METHODS: Healthy volunteers performed preload changes while simultaneously wearing a non-invasive, pulse-contour stroke volume (SV) monitor, a bioreactance SV monitor and a wireless, wearable Doppler ultrasound patch over the common carotid artery. The sensitivity and specificity for detecting preload change over 3 temporal windows (early, middle and late) was assessed. RESULTS: 40 preload changes were recorded in total (20 increase, 20 decrease). Immediately, the wearable Doppler had high sensitivity (100%) and specificity (100%) for detecting preload change with an area under the receiver operator curve (AUROC) of 0.98 for both velocity time integral (VTI, 10.5% threshold) and corrected flow time (FTc, 2.5% threshold). The sensitivity, specificity and AUROC for non-invasive pulse contour were equally good (9% SV threshold). For bioreactance, a 13% SV threshold immediately detected preload change with a sensitivity, specificity and AUROC of 60%, 95% and 0.75, respectively. After two SV outputs following preload change, the sensitivity, specificity and AUROC of bioreactance improved to 70%, 90% and 0.85, respectively. CONCLUSIONS: Carotid Doppler ultrasound and non-invasive pulse contour detected rapid hemodynamic change with equal accuracy; bioreactance improved over time. Algorithm-lag should be considered when interpreting clinical studies.
- Published
- 2022
40. Measuring the accuracy of cardiac output using POCUS: the introduction of artificial intelligence into routine care
- Author
-
Shaikh, Faisal, Kenny, Jon-Emile, Awan, Omar, Markovic, Daniela, Friedman, Oren, He, Tao, Singh, Sidharth, Yan, Peter, Qadir, Nida, and Barjaktarevic, Igor
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Bioengineering ,Clinical Research ,Biomedical Imaging ,4.2 Evaluation of markers and technologies ,Detection ,screening and diagnosis ,Velocity time integral ,VTI ,Point-of-care ultrasound ,POCUS ,Hemodynamic monitoring ,Cardiac output ,Artificial intelligence ,Medical biotechnology - Abstract
BackgroundShock management requires quick and reliable means to monitor the hemodynamic effects of fluid resuscitation. Point-of-care ultrasound (POCUS) is a relatively quick and non-invasive imaging technique capable of capturing cardiac output (CO) variations in acute settings. However, POCUS is plagued by variable operator skill and interpretation. Artificial intelligence may assist healthcare professionals obtain more objective and precise measurements during ultrasound imaging, thus increasing usability among users with varying experience. In this feasibility study, we compared the performance of novice POCUS users in measuring CO with manual techniques to a novel automation-assisted technique that provides real-time feedback to correct image acquisition for optimal aortic outflow velocity measurement.Methods28 junior critical care trainees with limited experience in POCUS performed manual and automation-assisted CO measurements on a single healthy volunteer. CO measurements were obtained using left ventricular outflow tract (LVOT) velocity time integral (VTI) and LVOT diameter. Measurements obtained by study subjects were compared to those taken by board-certified echocardiographers. Comparative analyses were performed using Spearman's rank correlation and Bland-Altman matched-pairs analysis.ResultsAdequate image acquisition was 100% feasible. The correlation between manual and automated VTI values was not significant (p = 0.11) and means from both groups underestimated the mean values obtained by board-certified echocardiographers. Automated measurements of VTI in the trainee cohort were found to have more reproducibility, narrower measurement range (6.2 vs. 10.3 cm), and reduced standard deviation (1.98 vs. 2.33 cm) compared to manual measurements. The coefficient of variation across raters was 11.5%, 13.6% and 15.4% for board-certified echocardiographers, automated, and manual VTI tracing, respectively.ConclusionsOur study demonstrates that novel automation-assisted VTI is feasible and can decrease variability while increasing precision in CO measurement. These results support the use of artificial intelligence-augmented image acquisition in routine critical care ultrasound and may have a role for evaluating the response of CO to hemodynamic interventions. Further investigations into artificial intelligence-assisted ultrasound systems in clinical settings are warranted.
- Published
- 2022
41. Chronic Obstructive Pulmonary Disease is Not Associated with In-Hospital Mortality in COVID-19: An Observational Cohort Analysis
- Author
-
Toppen, William, Yan, Peter, Markovic, Daniela, Shover, Carolyn M, Buhr, Russell G, Fulcher, Jennifer A, Tashkin, Donald P, and Barjaktarevic, Igor
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Emerging Infectious Diseases ,Lung ,Clinical Research ,Chronic Obstructive Pulmonary Disease ,Infectious Diseases ,Coronaviruses ,Respiratory ,Good Health and Well Being ,Humans ,Pulmonary Disease ,Chronic Obstructive ,COVID-19 ,Hospital Mortality ,Cohort Studies ,Aspirin ,COPD ,survival ,critical illness ,ARDS ,Cardiorespiratory Medicine and Haematology ,Respiratory System ,Cardiovascular medicine and haematology - Abstract
BackgroundChronic obstructive pulmonary disease (COPD) is associated with worsened outcomes in COVID-19 (coronavirus disease 2019). However, data remain fraught with heterogeneity and bias from comorbid conditions. Additionally, data on the impact of COPD-specific factors, such as pre-hospital medications and pulmonologist involvement, remain sparse.ObjectiveWe report a single-center analysis of COPD patients hospitalized with COVID-19 compared to those without COPD. Primary outcomes include ICU admission, mechanical ventilation, and in-hospital mortality.MethodsWe evaluated all patients ≥40 years admitted with PCR-confirmed COVID-19 between February 2020 and February 2021. COPD was defined by documented ICD-10 diagnosis of COPD, confirmed smoking history, and active bronchodilator use. We compared outcomes between COPD patients and the remainder of the COVID-19 cohort. Multivariable analyses were adjusted for age, sex, smoking status, and comorbid conditions.ResultsOf 1537 hospitalized COVID-19 patients, 122 (7.9%) carried a diagnosis of COPD. The COPD cohort was older (74 ± 13 vs 66 ± 15 years, P < 0.001) and more often former smokers (P < 0.001). Comorbid conditions including diabetes, cardiovascular disease, and kidney disease were more prevalent in the COPD group (P < 0.001). After adjusting for comorbid conditions, the COPD cohort had higher severity scores and trended towards fewer hospital-free days. Among patients with COPD, pre-hospital use of aspirin was associated with decreased ICU admissions (aHR 0.56, P = 0.049) and mechanical ventilation (aHR 0.25, P = 0.008), while LAMAs (long-acting muscarinic antagonists) were associated with decreased in-hospital mortality (aHR 0.34, P = 0.047). Involvement of pulmonology in pre-hospital management of COPD was not found to significantly affect outcomes.ConclusionWhen corrected for comorbid illnesses, COPD was associated with more severe disease but not with increased ICU admission, mechanical ventilation, or in-hospital mortality rates. Among COPD patients, prehospital treatment with aspirin and COPD-directed therapies were associated with improved outcomes.
- Published
- 2022
42. Cannabis consumption is associated with lower COVID-19 severity among hospitalized patients: a retrospective cohort analysis
- Author
-
Shover, Carolyn M, Yan, Peter, Jackson, Nicholas J, Buhr, Russell G, Fulcher, Jennifer A, Tashkin, Donald P, and Barjaktarevic, Igor
- Subjects
Health Sciences ,Traditional ,Complementary and Integrative Medicine ,Drug Abuse (NIDA only) ,Clinical Research ,Substance Misuse ,Respiratory ,Good Health and Well Being ,COVID-19 ,Cannabis ,Outcomes ,Respiratory failure ,ARDS ,Traditional ,complementary and integrative medicine - Abstract
BackgroundWhile cannabis is known to have immunomodulatory properties, the clinical consequences of its use on outcomes in COVID-19 have not been extensively evaluated. We aimed to assess whether cannabis users hospitalized for COVID-19 had improved outcomes compared to non-users.MethodsWe conducted a retrospective analysis of 1831 patients admitted to two medical centers in Southern California with a diagnosis of COVID-19. We evaluated outcomes including NIH COVID-19 Severity Score, need for supplemental oxygen, ICU (intensive care unit) admission, mechanical ventilation, length of hospitalization, and in-hospital death for cannabis users and non-users. Cannabis use was reported in the patient's social history. Propensity matching was used to account for differences in age, body-mass index, sex, race, tobacco smoking history, and comorbidities known to be risk factors for COVID-19 mortality between cannabis users and non-users.ResultsOf 1831 patients admitted with COVID-19, 69 patients reported active cannabis use (4% of the cohort). Active users were younger (44 years vs. 62 years, p < 0.001), less often diabetic (23.2% vs 37.2%, p < 0.021), and more frequently active tobacco smokers (20.3% vs. 4.1%, p < 0.001) compared to non-users. Notably, active users had lower levels of inflammatory markers upon admission than non-users-CRP (C-reactive protein) (3.7 mg/L vs 7.6 mg/L, p < 0.001), ferritin (282 μg/L vs 622 μg/L, p < 0.001), D-dimer (468 ng/mL vs 1140 ng/mL, p = 0.017), and procalcitonin (0.10 ng/mL vs 0.15 ng/mL, p = 0.001). Based on univariate analysis, cannabis users had significantly better outcomes compared to non-users as reflected in lower NIH scores (5.1 vs 6.0, p < 0.001), shorter hospitalization (4 days vs 6 days, p < 0.001), lower ICU admission rates (12% vs 31%, p < 0.001), and less need for mechanical ventilation (6% vs 17%, p = 0.027). Using propensity matching, differences in overall survival were not statistically significant between cannabis users and non-users, nevertheless ICU admission was 12 percentage points lower (p = 0.018) and intubation rates were 6 percentage points lower (p = 0.017) in cannabis users.ConclusionsThis retrospective cohort study suggests that active cannabis users hospitalized with COVID-19 had better clinical outcomes compared with non-users, including decreased need for ICU admission or mechanical ventilation. However, our results need to be interpreted with caution given the limitations of a retrospective analysis. Prospective and observational studies will better elucidate the effects cannabis use in COVID-19 patients.
- Published
- 2022
43. Postoperative Trapped Lung After Orthotopic Liver Transplantation is a Predictor of Increased Mortality.
- Author
-
Cuk, Natasha, Melamed, Kathryn H, Vangala, Sitaram, Salah, Ramy, Miller, W Dwight, Swanson, Sarah, Dai, David, Antongiorgi, Zarah, Wang, Tisha, Agopian, Vatche G, Dinorcia, Joseph, Farmer, Douglas G, Yanagawa, Jane, Kaldas, Fady M, and Barjaktarevic, Igor
- Subjects
Lung ,Humans ,Pneumonia ,Pleural Effusion ,Disease Progression ,Liver Transplantation ,Risk Factors ,Retrospective Studies ,Adult ,hepatic hydrothorax ,liver transplantation ,pleural effusions ,pneumothorax-ex-vacuo ,trapped lung ,Digestive Diseases ,Transplantation ,Liver Disease ,Organ Transplantation ,Clinical Research ,6.4 Surgery ,Evaluation of treatments and therapeutic interventions ,Good Health and Well Being ,Clinical Sciences ,Surgery - Abstract
Pleural effusions are a common complication of orthotopic liver transplantation (OLT), and chronic post-OLT pleural effusions have been associated with worse outcomes. Furthermore, "trapped lung" (TL), defined as a restrictive fibrous visceral pleural peel preventing lung re-expansion, may have prognostic significance. We performed a retrospective analysis of adult OLT recipients over a 9-year period at UCLA Medical Center. Post-OLT patients with persistent pleural effusions, defined by the presence of pleural fluid requiring drainage one to 12 months after OLT, were included for analysis. Outcomes for patients with and without TL were compared using univariate and multivariate analysis. Of the 1722 patients who underwent OLT, 117 (7%) patients met our criteria for persistent postoperative pleural effusion, and the incidence of TL was 21.4% (25/117). Compared to patients without TL, those with TL required more surgical pleural procedures (OR 59.8, 95%CI 19.7-181.4, p < 0.001), spent more days in the hospital (IRR 1.56, 95%CI 1.09-2.23, p = 0.015), and had a higher risk of mortality (HR 2.47, 95%CI 1.59-3.82, p < 0.001) following transplant. In sum, we found that post-OLT TL was associated with higher morbidity, mortality, and healthcare utilization. Future prospective investigation is warranted to further clarify the risk factors for developing postoperative pleural effusions and TL.
- Published
- 2022
44. Guidance on Mitigating the Risk of Transmitting Respiratory Infections During Nebulization by the COPD Foundation Nebulizer Consortium
- Author
-
Biney, Isaac N., Ari, Arzu, Barjaktarevic, Igor Z., Carlin, Brian, Christiani, David C., Cochran, Lauren, Drummond, M. Bradley, Johnson, Karmon, Kealing, Dan, Kuehl, Philip J., Li, Jie, Mahler, Donald A., Martinez, Sergio, Ohar, Jill, Radonovich, Lewis J., Sood, Akshay, Suggett, Jason, Tal-Singer, Ruth, Tashkin, Donald, Yates, Julie, Cambridge, Lisa, Dailey, Patricia A., Mannino, David M., and Dhand, Rajiv
- Published
- 2024
- Full Text
- View/download PDF
45. Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine Reduces Exacerbation Rate and Risk in Patients With Moderate to Severe COPD
- Author
-
Sciurba, Frank C., Christenson, Stephanie A., Rheault, Tara, Bengtsson, Thomas, Rickard, Kathleen, and Barjaktarevic, Igor Z.
- Published
- 2024
- Full Text
- View/download PDF
46. Bronchodilator Responsiveness in Tobacco-Exposed People With or Without COPD
- Author
-
Alexis, Neil E., Anderson, Wayne H., Arjomandi, Mehrdad, Barjaktarevic, Igor, Barr, R. Graham, Basta, Patricia, Bateman, Lori A., Bhatt, Surya P., Bleecker, Eugene R., Boucher, Richard C., Bowler, Russell P., Christenson, Stephanie A., Comellas, Alejandro P., Cooper, Christopher B., Couper, David J., Criner, Gerard J., Crystal, Ronald G., Curtis, Jeffrey L., Doerschuk, Claire M., Dransfield, Mark T., Drummond, Brad, Freeman, Christine M., Galban, Craig, Han, MeiLan K., Hansel, Nadia N., Hastie, Annette T., Hoffman, Eric A., Huang, Yvonne, Kaner, Robert J., Kanner, Richard E., Kleerup, Eric C., Krishnan, Jerry A., LaVange, Lisa M., Lazarus, Stephen C., Martinez, Fernando J., Meyers, Deborah A., Moore, Wendy C., Newell, John D., Jr., Paine, Robert, III, Paulin, Laura, Peters, Stephen P., Pirozzi, Cheryl, Putcha, Nirupama, Oelsner, Elizabeth C., O’Neal, Wanda K., Ortega, Victor E., Raman, Sanjeev, Rennard, Stephen I., Tashkin, Donald P., Wells, J. Michael, Wise, Robert A., Woodruff, Prescott G., Fortis, Spyridon, Quibrera, Pedro M., Dransfield, Mark B., Dolezal, Brett A., Kim, Victor, Barjaktarevic, Igor Z., and Couper, David
- Published
- 2023
- Full Text
- View/download PDF
47. Shock Management Without Formal Fluid Responsiveness Assessment: A Retrospective Analysis of Fluid Responsiveness and Its Outcomes.
- Author
-
Hong, Andrew, Villano, Nicholas, Toppen, William, Elizabeth Aquije, Montoya, Berlin, David, Cannesson, Maxime, and Barjaktarevic, Igor
- Subjects
fluid responsiveness ,fluid resuscitation ,hemodialysis ,hemodynamic monitoring ,shock - Abstract
BACKGROUND: In order to quantify fluid administration and evaluate the clinical consequences of conservative fluid management without hemodynamic monitoring in undifferentiated shock, we analyzed previously collected data from a study of carotid Doppler monitoring as a predictor of fluid responsiveness (FR). METHODS: This study was a retrospective analysis of data collected from a single tertiary academic center from a previous study. Seventy-four patients were included for post-hoc analysis, and 52 of them were identified as fluid responsive (cardiac output increase > 10% with passive leg raise) according to NICOMTM bioreactance monitoring (Cheetah Medical, Newton Center, MA, USA). Treating teams provided standard of care conservative fluid resuscitation but were blinded to independently performed FR testing results. Outcomes were compared between fluid responsive and fluid non-responsive patients. Primary outcome measures were volume fluids administered and net fluid balance 24- and 72-hour post-FR assessment. Secondary outcome measures included change in vasopressor requirements, mean peak lactate levels, length of hospital/intensive care unit stay, acute respiratory failure, hemodialysis requirement, and durations of vasopressors and mechanical ventilation. RESULTS: Mean fluids administered within 72 hours were similar between fluid non-responsive and fluid responsive patients (139 mL/kg [95% confidence interval [CI]: 102.00-175.00] vs. 136 mL/kg [95% CI: 113.00-158.00], p = 0.92, respectively). We observed an insignificant trend toward higher 28-day mortality among fluid non-responsive patients (36% vs. 19%, p = 0.14). Volume of fluids administered significantly correlated with adverse outcomes such as increased hemodialysis requirements (32 patients, 43%), (odds ratio [OR] = 1.7200, p = 0.0018). Subgroup analysis suggested administering ≥ 30 mL/kg fluids to fluid responsive patients had a trend toward increased mortality (25% vs. 0%, p = 0.09) and a significant increase in hemodialysis (55% vs. 17%, p = 0.024). CONCLUSIONS: Without formal FR assessment, similar amounts of total fluids were administered in both fluid responsive and non-responsive patients. As greater volumes of intravenous fluids administered were associated with adverse outcomes, we suggest that dedicated FR assessment may be a beneficial utility in early shock resuscitation.
- Published
- 2021
48. Genetic and non-genetic factors affecting the expression of COVID-19-relevant genes in the large airway epithelium
- Author
-
Kasela, Silva, Ortega, Victor E, Martorella, Molly, Garudadri, Suresh, Nguyen, Jenna, Ampleford, Elizabeth, Pasanen, Anu, Nerella, Srilaxmi, Buschur, Kristina L, Barjaktarevic, Igor Z, Barr, R Graham, Bleecker, Eugene R, Bowler, Russell P, Comellas, Alejandro P, Cooper, Christopher B, Couper, David J, Criner, Gerard J, Curtis, Jeffrey L, Han, MeiLan K, Hansel, Nadia N, Hoffman, Eric A, Kaner, Robert J, Krishnan, Jerry A, Martinez, Fernando J, McDonald, Merry-Lynn N, Meyers, Deborah A, Paine, Robert, Peters, Stephen P, Castro, Mario, Denlinger, Loren C, Erzurum, Serpil C, Fahy, John V, Israel, Elliot, Jarjour, Nizar N, Levy, Bruce D, Li, Xingnan, Moore, Wendy C, Wenzel, Sally E, Zein, Joe, Langelier, Charles, Woodruff, Prescott G, Lappalainen, Tuuli, and Christenson, Stephanie A
- Subjects
Biological Sciences ,Genetics ,Lung ,Clinical Research ,Infectious Diseases ,Prevention ,Emerging Infectious Diseases ,Human Genome ,2.2 Factors relating to the physical environment ,Aetiology ,2.1 Biological and endogenous factors ,Infection ,Respiratory ,Good Health and Well Being ,Adult ,Aged ,Aged ,80 and over ,Angiotensin-Converting Enzyme 2 ,Asthma ,Bronchi ,COVID-19 ,Cardiovascular Diseases ,Gene Expression ,Genetic Variation ,Humans ,Middle Aged ,Obesity ,Pulmonary Disease ,Chronic Obstructive ,Quantitative Trait Loci ,Respiratory Mucosa ,Risk Factors ,SARS-CoV-2 ,Smoking ,ACE2 ,eQTL ,Bronchial epithelium ,NHLBI SubPopulations and InteRmediate Outcome Measures In COPD Study ,NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium ,Clinical Sciences - Abstract
BackgroundThe large airway epithelial barrier provides one of the first lines of defense against respiratory viruses, including SARS-CoV-2 that causes COVID-19. Substantial inter-individual variability in individual disease courses is hypothesized to be partially mediated by the differential regulation of the genes that interact with the SARS-CoV-2 virus or are involved in the subsequent host response. Here, we comprehensively investigated non-genetic and genetic factors influencing COVID-19-relevant bronchial epithelial gene expression.MethodsWe analyzed RNA-sequencing data from bronchial epithelial brushings obtained from uninfected individuals. We related ACE2 gene expression to host and environmental factors in the SPIROMICS cohort of smokers with and without chronic obstructive pulmonary disease (COPD) and replicated these associations in two asthma cohorts, SARP and MAST. To identify airway biology beyond ACE2 binding that may contribute to increased susceptibility, we used gene set enrichment analyses to determine if gene expression changes indicative of a suppressed airway immune response observed early in SARS-CoV-2 infection are also observed in association with host factors. To identify host genetic variants affecting COVID-19 susceptibility in SPIROMICS, we performed expression quantitative trait (eQTL) mapping and investigated the phenotypic associations of the eQTL variants.ResultsWe found that ACE2 expression was higher in relation to active smoking, obesity, and hypertension that are known risk factors of COVID-19 severity, while an association with interferon-related inflammation was driven by the truncated, non-binding ACE2 isoform. We discovered that expression patterns of a suppressed airway immune response to early SARS-CoV-2 infection, compared to other viruses, are similar to patterns associated with obesity, hypertension, and cardiovascular disease, which may thus contribute to a COVID-19-susceptible airway environment. eQTL mapping identified regulatory variants for genes implicated in COVID-19, some of which had pheWAS evidence for their potential role in respiratory infections.ConclusionsThese data provide evidence that clinically relevant variation in the expression of COVID-19-related genes is associated with host factors, environmental exposures, and likely host genetic variation.
- Published
- 2021
49. High-Flow Nasal Oxygen Therapy in Acute Hypoxemic Respiratory Failure: Concise Review on Technology and Initial Methodology.
- Author
-
Guia, Miguel, Alpay, Nilgun, Gerardo, António, Madney, Yasmin, Abdelrahim, Mohamed, Saeed, Haitham, Harb, Hadeer, Gonçalves, Gil, Cabrita, Bruno, Alqahtani, Jaber, El-Khatib, Mohamad, Gómez-Ríos, Manuel, Fakharian, Atefeh, Ciobanu, Laura, Karim, Habib, Piervincenzi, Edoardo, Scharffenberg, Martin, Steiropoulos, Paschalis, LeMaster, William, Barjaktarevic, Igor, Wittenstein, Jakob, Diaz-Abad, Montserrat, Perren, Andreas, Nicolini, Antonello, Spadaro, Savino, Garuti, Giancarlo, Petroianni, Angelo, and Esquinas, Antonio
- Abstract
High-flow nasal cannula oxygen therapy (HFNCOT) system consists of an air/oxygen supply system capable of delivering up to 100% humidified and heated oxygen at a flow rate of up to 80 L/min. The system includes a blender, active humidifier, single heated tube, and nasal cannula. HFNCOT has many physiological advantages compared with other standard oxygen therapies, such as anatomical dead space washout, more constant fraction of inspired oxygen, positive end-expiratory (PEEP) effect, supplement of adequate humidification and maintenance of muco-ciliary function. HFNCOT is mostly used for hypoxemic acute respiratory failure, although it also has other indications. HFNCOT is a common choice of physicians as its technology makes it more silent and comfortable. Though HFNCOT is used in many clinical settings, there is a lack of publications addressing devices and initial settings. We present a review on HFNCOT, with focus on device and application methodology.
- Published
- 2021
50. Defining Resilience to Smoking-related Lung Disease: A Modified Delphi Approach from SPIROMICS.
- Author
-
Oh, Anita L, Mularski, Richard A, Barjaktarevic, Igor, Barr, R Graham, Bowler, Russell P, Comellas, Alejandro P, Cooper, Christopher B, Criner, Gerard J, Han, MeiLan K, Hansel, Nadia N, Hoffman, Eric A, Kanner, Richard E, Krishnan, Jerry A, Paine, Robert, Parekh, Trisha M, Peters, Stephen P, Christenson, Stephanie A, Woodruff, Prescott G, and SPIROMICS Smoking Resilience Group
- Subjects
SPIROMICS Smoking Resilience Group ,Lung ,Humans ,Pulmonary Disease ,Chronic Obstructive ,Forced Expiratory Volume ,Spirometry ,Smoking ,biomarkers ,chronic obstructive pulmonary disease ,consensus development ,smoking ,spirometry ,Tobacco ,Tobacco Smoke and Health ,Lung Cancer ,Chronic Obstructive Pulmonary Disease ,Clinical Research ,Cancer ,Respiratory - Abstract
Rationale: Diagnosis of chronic obstructive pulmonary disease (COPD) relies on abnormal spirometry. However, spirometry may underestimate the effects of smoking, missing smokers with respiratory disease who have minimal or no airflow obstruction. Objectives: To develop a multidimensional definition of a lung-related "resilient smoker" that is useful in research studies and then identify a resilient smoker subgroup in the SPIROMICS (SubPopulations and InteRmediate Outcome Measures In COPD Study) cohort using this definition. Methods: We performed a three-round modified Delphi survey among a panel of COPD experts to identify and reach a consensus on clinical and radiographic domains to be included in a lung-related resilient smoker definition. Consensus on domains of resilience was defined as ⩾80% of experts voting "agree" or "strongly agree" on a 5-point Likert scale. The Delphi-derived definition of resilience was applied to SPIROMICS to identify resilient smokers, whom we then characterized using known biomarkers of COPD. Results: Consensus was achieved on 6 of 12 diagnostic items, which include cough and sputum production, dyspnea, radiographic measures of emphysema and small airways disease, exacerbations, and decline in forced expiratory volume in 1 second. Although 892 SPIROMICS participants were classified as smokers with preserved lung function by spirometry, only 149 participants (16.7%) qualified as resilient smokers by our definition. Blood biomarker expression of CRP (C-reactive protein) and sTNFRSF1A (soluble tumor necrosis receptor factor1A) was lower in resilient than nonresilient smokers (P = 0.02 and P = 0.03). Conclusions: A Delphi-derived consensus definition of resilient smoker identified 83.3% of smokers with preserved spirometry as "nonresilient" based on the presence of adverse effects of smoking on the lung. Resilient smokers were biologically distinct from nonresilient smokers based on CRP measurements. Clinical trial registered with ClinicalTrials.gov (NCT01969344).
- Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.